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ABSTRACT OF THE DISSERTATION
Host Determinants of Protection and Pathogenesis during Chikungunya Virus Infection
by
Lindsey Elaine Cook
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2018
Professor Deborah J. Lenschow, Chairperson
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes acute and
chronic polyarthritis. The virus has rapidly emerged over the last decade, and in 2013, CHIKV
spread to the Western Hemisphere for the first time, infecting more than 1.8 million people.
CHIKV targets the joints and musculoskeletal tissues, resulting in severe myalgia and symmetric
polyarthritis that clinically mimics rheumatoid arthritis. Currently, no approved treatment is
effective in preventing or controlling CHIKV infection or disease. Pathogenesis of CHIKV is still
poorly understood but is thought to reflect an interplay between viral replication and detrimental
immune responses. CHIKV patients have increased numbers of circulating CD4+ and CD8+ T
cells, and mice lacking or depleted of CD4+ T cells show reduced foot swelling and arthritis during
acute CHIKV infection, suggesting that CD4+ T cells contribute to the pathology of arthritis.
Additionally, monocytes and/or macrophages are also thought to promote disease because
depletion of macrophages with clodronate liposomes or inhibiting production of monocyte
chemoattractant protein-1 (MCP-1) with bindarit improved symptoms in animal models. Though
immunopathology appears to play an important role in CHIKV pathogenesis, not all host responses
are detrimental. Central to controlling CHIKV and other alphavirus infections is the type I
xi

interferon (IFN-I) response, as mice lacking the IFN-I receptor rapidly succumb to infection. IFNI are well known for their antiviral and immunomodulatory properties, but their mechanism of
action during CHIKV infection is poorly understood.
IFN-Is are composed of 14 IFN-α subtypes and single forms of IFN-β, IFN-ε, IFN-κ, and
IFN-ω, and despite their central role in protection against a number of viruses, little is known about
the biological roles of individual IFN-I subtypes during viral infection. To address this issue we
used genetic deletion mutants and blockade with antibodies targeting specific IFN subtypes to
determine the contributions of IFN-α and IFN-β during acute CHIKV infection. We found that
both IFN-α and IFN-β play important protective roles in limiting clinical CHIKV disease, but they
do so by distinct mechanisms. The loss of IFN-α (through IRF7 knockout or IFN-α blocking Abs)
resulted in increased CHIKV replication and dissemination. In contrast, loss of IFN-β (through
IFN-β knockout or IFN-β blocking Abs) had minimal impact on viral replication and
dissemination. Instead, the loss of IFN-β lead to increased neutrophil recruitment and elevated IL9 induction. Further, the increased clinical disease observed in IFN-β knockout mice could be
rescued with neutrophil depletion. Thus, our findings suggest distinct protective roles for the IFNI subtypes during CHIKV infection, with IFN-α functioning to limit early viral replication and
spread and IFN-β modulating neutrophil-mediated immunopathology.
Previous data have shown that immune cells and proinflammatory cytokines contribute to
CHIKV arthritis in mice. Because chronic CHIKV arthritis is clinically similar to seronegative
rheumatoid arthritis, we examined the efficacy of several U.S. Food and Drug Administration
(FDA)-approved rheumatoid arthritis therapies in a mouse model of CHIKV infection. We
identified CTLA4-Ig (abatacept) as a disease-modifying antirheumatic drug (DMARD) with
efficacy during acute CHIKV arthritis. CTLA4-Ig, which blocks T cell activation, reduced T cell
xii

accumulation in the joints of infected animals without affecting viral replication. When paired with
the neutralizing anti-CHIKV human monoclonal antibody, 4N12, it was highly effective at
reducing joint inflammation, periarticular swelling, migration of inflammatory leukocytes, and
infection, even when administered several days after virus inoculation. Thus, combination of antiinflammatory and antibody-based antiviral therapy may serve as a model for treating humans with
arthritis caused by CHIKV or other related viruses.
Collectively, these data provide important mechanistic insight into the host factors that
control and promote CHIKV pathogenesis. Continued pursuit of defining interactions between
CHIKV and the host immune responses will be paramount in developing effective therapeutics
and vaccines to combat CHIKV and other emerging tropical diseases, which remain a global health
and economic burden.

xiii

Chapter 1
Introduction

1

1.1 Chikungunya virus
1.1.1 Overview
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes acute and
chronic polyarthritis. The virus has rapidly emerged over the last decade, with millions of people
infected worldwide. CHIKV targets the joints and musculoskeletal tissues, resulting in severe
myalgia and symmetric polyarthritis that can last for months to years after infection in some
patients. Currently, no approved treatment is effective in preventing or controlling CHIKV
infection or disease. Pathogenesis of CHIKV is still poorly understood but is thought to reflect
interplay between viral replication and detrimental immune responses.

1.1.2 Epidemiology and Transmission
CHIKV was first isolated from a febrile patient in Tanzania in 1952, and its name comes
from a Makonde phrase that means “to become contorted” or “that which bends up,” which
describes the posture of those suffering from debilitating CHIKV arthritis1. In endemic rural areas,
CHIKV is maintained in an enzootic cycle involving nonhuman primates and mosquitoes,
occasionally causing short-lived sporadic outbreaks in urban areas of Africa, which rely on humanmosquito-human transmission2. Three lineages of CHIKV have been defined: East/Central/South
African (ECSA), West African, and Asian. The West African strain has mostly been associated
with enzootic transmission and occasional small outbreaks of human disease confined to West
Africa. In contrast, the ECSA and Asian genotypes have rapidly expanded to new regions and have
caused numerous urban outbreaks.
Beginning in 2004 a severe outbreak with the ECSA strain began in the coastal region of
Kenya on Lamu Island and Mombasa. CHIKV then quickly spread to surrounding countries and
2

islands of the Indian Ocean. During this outbreak, the French island of La Réunion experienced a
particularly severe outbreak, with over one third of the population infected with CHIKV between
2005 and 20063,4. During the La Réunion outbreak, more severe disease manifestations, such as
encephalopathy and mortality, were observed5,6. Studies comparing a clinical isolate from the La
Réunion outbreak (LR OPY2006) to a previous strain (Senegal, 1983) revealed that increased
infection of myofibers may have contributed to the increased disease severity seen on La Réunion7.
When CHIKV re-emerged in India, millions of people were infected, and an infected traveler
returning to Italy from India resulted in a small outbreak there, which was the first instance of local
CHIKV transmission in Europe8. In 2013, the Asian strain of CHIKV emerged in the Caribbean
on the island of Saint Martin, and since its introduction to the Americas, there have been over 1.8
million suspected cases in South and Central America9. With its introduction to the Western
Hemisphere, the United States has seen an increase in the number of imported cases, and for the
first time, local transmission was reported in Florida10.
Historically, CHIKV was primarily transmitted by the Aedes aegypti mosquito, but in 2006
the ECSA genotype acquired a single mutation (A226V) in its E1 envelope glycoprotein that
enhanced its replication in the A. albopictus mosquito, which has more temperate geographical
spread than A. aegypti11. Interestingly, the Asian strain is genetically constrained in its ability to
adapt to the A. albopictus mosquito12. Transmission by A. albopictus played an important role in
outbreaks that occurred in Italy, and increases the potential for outbreaks in other more temperate
regions like the United States8. Despite the unprecedented rapid spread of the ECSA in the Indian
Ocean region, it was the Asian lineage that emerged in the Caribbean and the Americas, and thus,
the outbreaks in the Western Hemisphere have primarily been transmitted by A. aegypti. In 2014,
the ECSA was reported to have been introduced in Brazil, raising concerns for the potential of
3

increased spread into the United States, where A. albopictus has great geographical range13.
Collectively, in little more than a decade, CHIKV has reemerged as a global pathogen, infecting
millions of people and causing economic damage in more than 50 countries2,14.

1.1.3 Symptoms and Treatment
After being bitten by a mosquito carrying CHIKV and an incubation period of 2-6 days,
infections in humans can manifest with fever, a maculopapular-like rash, malaise, myalgia, and
severe polyarthralgia and polyarthritis15,16. During the ongoing outbreak, there was also reports of
more severe symptoms, particularly in neonates, the elderly, or patients with other underlying
medical conditions. These severe clinical features include neurologic and cardiac manifestations,
and for the first time, there were reports of fatality associated with CHIKV infection5,6. Unlike
other arthritogenic viruses, CHIKV infections are 90-95% symptomatic17. Patients presenting with
acute CHIKV arthralgia usually experience symmetrical joint pain in the peripheral joints, such as
wrists, knees, ankles, and the small joints of the hand. Joint pain is often accompanied with
arthritis, with joints displaying swelling and tenderness. Acute disease is usually self-limiting and
typically resolves in 7-10 days, however a large subset of patients can develop chronic symptoms
that last from months to years after infection. There are reports that anywhere from 20 to 60% of
infected individuals can develop chronic arthritis symptoms following CHIKV infection18–21.
Epidemiological predictions suggest that the number of people in the Americas suffering from
chronic CHIKV symptoms is 400,00022. Chronic CHIKV arthritis is clinically similar to patients
with seronegative rheumatoid arthritis (RA), with the hands, wrists, feet, and ankles primarily
affected23.
There are currently no approved specific antiviral therapies or vaccines available for
CHIKV infection. Treatment for acute and chronic symptoms is primarily supportive care to
4

reduce fever and pain. A couple of small studies have reported improvement of CHIKV symptoms
with chloroquine phosphate treatment, an antimalarial drug, but a study with a large cohort of
patients from La Réunion found no improvement24–26. In recent years, studies have begun to
address the need for new therapeutic options in CHIKV infection. A number of compounds have
been showed to inhibit CHIKV replication in cell culture, and several treatment strategies in animal
models of CHIKV infection have provided some hope for alleviation of CHIKV symptoms 27.
Monoclonal neutralizing antibodies isolated from infected patients have been protective when
administered prophylactically or therapeutically in highly susceptible neonatal mice or
immunocompromised mice28,29. Furthermore, a loss-of-function screening approach identified a
number of pro-viral host factors with pre-existing small-molecule inhibitors available30. Several
of these small-molecule inhibitors were efficacious in vivo, and the protective effects were
enhanced when used in combination. Collectively, these studies demonstrate that targeting viral
and/or host pathways may be promising, but much work remains to be done to develop and test
effective treatment options for those suffering with CHIKV arthritis, particularly for those
suffering from chronic symptoms.

1.1.4 Replication Cycle
CHIKV and other alphaviruses are members of the Togaviridae family of viruses, and as
such, they are enveloped viruses with a positive-sense, single stranded RNA genome. The CHIKV
genome is approximately 11,800 base pairs in length and contains a 5’ untranslated region,
followed by nonstructural genes, structural genes with a subgenomic promoter, and a 3’
untranslated region. Replication in mammalian cells takes place in the cytosol and in virallyinduced cytopathic vacuoles31. The replication cycle of CHIKV is summarized in Figure 1.1.

5

Alphaviruses enter susceptible cells by clathrin-mediated endocytosis, but the specific
mechanistic events for CHIKV binding and entry are still unclear32. Bona fide receptors have yet
to be identified, but glycosaminoglycans may serve as attachment factors for many susceptible cell
types33–35. Once CHIKV enters the endosomal compartment, the increased acidic environment
inside the endosome induces a conformational change in the virion envelope that exposes the E1
glycoprotein fusion loop36. This allows fusion of the virion envelope with the endosome
membrane, releasing the nucleocapsid into the cytosol. Alphavirus capsid proteins bind the host’s
large ribosomal subunit, and this interaction is thought to actively disassemble the nucleocapsid
and release the RNA genome into the cytosol37,38.
The CHIKV genome contains two open reading frames that encode for two polyproteins,
which are then cleaved into multiple proteins. First, the genome is translated by host machinery to
produce the nonstructural polyprotein P1234. This precursor is autocleaved by protease activity
located in nsP2 into P123 and nsP4, which make up a short-lived replicase that synthesizes a fulllength negative-sense RNA template31. Early negative-strand synthesis by the short-lived
P123/nsP4 replicase takes place at the plasma membrane in small, vesicular compartments called
spherules for a number of alphaviruses, including CHIKV39–43. The nsPs localize at the neck of
the spherules, which might serve to help shield double-stranded RNA (dsRNA) intermediates from
recognition by the host. The spherules are eventually internalized into large cytopathic vacuoles
(CPV-I), and P123 accumulation leads to complete processing of the polyprotein into nsP1, nsP2,
and nsP3, which together with nsP4 uses the negative-sense template for amplification of genomic
positive-sense RNA and transcription of subgenomic (26S) positive-sense RNA that encodes the
structural polyprotein.

6

The host machinery begins to translate the subgenomic RNA, and as the capsid protein is
translated, it is quickly released by autoproteolysis to begin forming nucleocapsids containing a
single genomic RNA molecule. Translation of the subgenomic RNA continues to generate an E3E2-6K-E1 product and a minor product (E3-E2-TF) that is the result of ribosomal
frameshifting44,45. The N-terminus of E3 contains a signal peptide that directs the 2 polyprotein
products into the host secretory pathway, and host protease cleavage yields pE2 (E3-E2), 6K or
transframe (TF), and E1. The roles of 6K and TF are still unclear. They do not seem to be
incorporated into virions, but may have ion-channel properties and play important roles in viral
budding46. E1 and E3-E2 continue through the secretory pathway and undergo several posttranslational modifications, including N-linked glycosylation, and E3 is released by the host
protease furin. E1 and E2 can now begin to form spikes on the plasma membrane31.
A second type of cytopathic vacuole (CPV-II) forms late in infection. Here, cytoplasmic
nucleocapsids associate with internalized E1 and E2 spikes, and a mature virion egresses and buds
from the cell47,48. It is worth noting that CPV-I and CPV-II formation appears to be specific to
mammalian cells infected with CHIKV. The CHIKV virion contains a lipid bilayer envelope
around an icosahedral nucleocapsid shell, which consists of 240 capsid copies and the genomic
RNA. The E1 and E2 glycoproteins form heterodimers on the envelope surface that are further
arranged into trimers to form an icosahedral lattice49. There is some evidence that CHIKV may be
spread by apoptotic blebs to uninfected neighboring cells in vitro, which would help avoid
detection by antibodies and aid infection of some non-permissive cells. Macrophages were
demonstrated to be infected after phagocytosing CHIKV-containing apoptotic blebs in vitro50.
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1.1.5 Animal Models
In the last 10-15 years, significant progress has been made to delineate the mechanisms
underlying disease pathogenesis. These advances have been made possible with the development
and use of animal models that recapitulate many aspects of human disease. The most commonly
used model is a mouse model of CHIKV arthritis. In this model adolescent and adult
immunocompetent mice are inoculated with CHIKV directly into the rear footpad, mimicking the
effects of a mosquito bite. This arthritis mouse model recapitulates many aspects of acute human
disease including viremia, viral replication in the joint and muscle tissues, and histopathological
signs of synovitis and myositis51–53. This route of CHIKV infection in mice causes a biphasic
pattern of foot swelling in the inoculated foot. In a WT mouse, the first peak of foot swelling occurs
2-3 days post infection (dpi) and is thought to arise from robust viral replication which drives cell
death, local proinflammatory cytokine production, and edema. The second peak (6-7 dpi) occurs
as infectious virus is cleared from the tissues and blood and is associated with an influx of
inflammatory infiltrates into the joint spaces and surrounding soft tissues that drive cytokine
production, synovitis, myositis, and edema51,52. Though clinical foot swelling resolves by 10-12
dpi, this model does encompass some aspects of chronic CHIKV disease. CHIKV RNA persists
in the joints of mice to at least 120 dpi, and there are signs of myositis and synovitis by
histopathology54,55. The pathogenesis of CHIKV in the arthritis model is further discussed in
section 1.1.7 and summarized in Figure 1.2
Other animal models have also been useful in determining mechanisms of CHIKV
pathogenesis. Infection of neonatal mice results in severe CHIKV disease that exhibits agedependent mortality. The severe symptoms observed in neonatal mice mimics many aspects of
human infants infected with CHIKV, including dissemination to the central nervous system56–58.
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Infection of adult cynomolgus macaques results in high viremia, viral dissemination, viral
persistence, and pathological features similar to human disease, and aged rhesus macaques show
persistent virus in the spleen59,60. The cumulative work from all of these models reveal that CHIKV
symptoms are the result of both extensive viral replication in the musculoskeletal and joint tissues,
as well as pathology driven by aspects of the host immune response (described in detail below).
Careful mapping of the viral and host determinants of pathogenesis will be needed to aid in the
development of effective therapeutics and vaccines to combat this global pathogen.

1.1.6 Tropism
Tropism: Cell Culture
When the severe CHIKV outbreak began in 2004, very little was known about CHIKV
biology. Early work sought to define the cell tropism of CHIKV in vitro. An early study tested a
large panel of immortalized and primary human cells for their ability to support CHIKV
replication61. They demonstrated that a variety human epithelial-derived cell lines, such as HeLa
and 293T cells, and primary fibroblasts (Hs 789.sk skin cells and MRC5 lung cells) were highly
susceptible to CHIKV infection. Additionally, an endothelial cell line isolated from bone marrow
(TrHBMEC cells), but not the brain (hCMEC/D3 cells), supported CHIKV replication. CHIKV
infection of cell lines and primary cells was highly cytopathic and associated with apoptosis. In
contrast, CHIKV did not replicate in lymphoid and monocyte cell lines, primary lymphocytes and
monocytes, or monocyte-derived dendritic cells. In this study, primary monocyte-derived
macrophages were the only immune cell population tested that was able to support CHIKV growth,
albeit to a much lesser extent than the epithelial and fibroblast cells61. Because the skin is the first
site of infection, another group sought to determine the response of keratinocytes to CHIKV
infection and found that human keratinocytes are refractory to CHIKV infection at a post-fusion
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step, but they were still able to produce cytokines and chemokines following CHIKV exposure62.
Additional work has shown that CHIKV can also infect primary human osteoblast cultures, which
leads to the production IL-6 and receptor activator of nuclear factor kappa-Β ligand (RANKL) and
inhibition of osteoprotegerin63.
Tropism: Acute Infection
After inoculation of immunocompetent mice in the skin, CHIKV RNA was detected by in
situ hybridization in the ipsilateral foot at 3 days post infection (dpi) in cells lining blood vessels,
skeletal muscle cells, cells in the dermis consistent with fibroblast morphology, cells in the
synovial membrane, and cells of the periosteum64. By 5 dpi, the cells lining the blood vessels
remained positive, but staining was diminished in the dermis and absent in the muscle. These data
and the observations from cell culture infections suggest that CHIKV targets a wide variety of
cells in the musculoskeletal and joint tissues, which is consistent with the clinical disease
manifestations. Whether immune cells, particularly monocytes and macrophages, are actively
infected during acute CHIKV infection remains unclear and controversial. Work from Lisa Ng’s
group showed that monocytes isolated from viremic patients were positive for CHIKV antigen
staining by flow cytometry, and this antigen positivity was lost when the samples were taken from
the same patients during the chronic phase65. However, time-course analysis of infection of human
monocytes in vitro suggest that monocytes might not support productive release of infectious
particles. Over time, the percent of infected monocytes marginally increased over the 0 hour time
point (35% versus 10%). Additionally, the viral load determined by RT-PCR remains constant
over time, and infectious virus in the supernatant substantially decreases over time65.Though the
authors concluded that monocytes could “sustain virus growth,” these data are more consistent
with a model in which CHIKV can bind and enter monocytes, but this ultimately yields a
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nonproductive infection. Nonproductively infected cells can be important sources of cytokines and
chemokines, and it may be that nonproductive-infected monocytes are important sources of IFN-I
(further discussed in section 1.2.4).
Tropism: Chronic Disease
Tropism for chronic CHIKV infection is still not well understood. CHIKV has not been
cultured from patient synovial fluid, but a biopsy of synovial tissue from a patient experiencing
chronic symptoms showed CHIKV antigen-positive perivascular macrophages and large numbers
of activated CD56+CD69+ NK cells and CD4+ T cells clustered around the CHIKV+ macrophage66.
Additionally, aged rhesus macaques show CHIKV RNA persistence in their spleens, and
additionally, a study with cynomolgus macaques showed that macrophages in the spleen were
positive for CHIKV antigen59,60. These studies suggest that persistent viral RNA and/or antigen
may be sustaining immune activation, which promotes continuous proinflammatory cytokine and
chemokine production. The sensitivity of assays used to detect CHIKV antigen or viral RNA has
made it difficult to identify the source and nature of persistent CHIKV RNA. Unpublished data
from our lab using a CHIKV-Cre fate-reporter system suggest that while CHIKV is highly
cytopathic in vitro, many cells are able to survive CHIKV infection in vivo. These cells seem to be
CD45-negative and are mostly located in the muscle and to a lesser extent in the dermis. Much
more work is needed to characterize the cellular players in harboring persistent CHIKV RNA.

1.1.7 Pathogenesis
Acute Pathogenesis: Innate Immune Responses
Evidence from patient samples and from animal models suggest that a robust innate
immune response is mounted following CHIKV infection. Several groups have characterized
proinflammatory cytokines and chemokines from serum of CHIKV patient cohorts. There have
11

been some discrepancies between the various cohorts, but IL-1β, IL-6, IFN-α, CCL2/MCP-1,
CXCL9/MIG, and CXCL10/IP-10 are among those that were upregulated in CHIKV patients
relative to healthy controls67–69. Macrophages and monocytes are rapidly recruited to the site of
infection in animal models52. Clodronate depletion of macrophages had a protective effect on
clinical disease, but worsened viremia, suggesting the macrophages may have a dual role in
promoting pathogenesis while also controlling viral replication51. Consistent with this, a study
showed that treatment with Bindarit, an inhibitor of CCL2 synthesis, reduced cellular infiltration
and CHIKV-associated bone loss70. However, the role of macrophages and monocytes may be
more complex, as mice deficient for CCR2, the receptor for CCL2, developed much more severe
and prolonged CHIKV arthritic disease that was due to compensatory recruitment of neutrophils
and eosinophils71. Indeed, recent work demonstrated that monocytes were protective in both RRV
and CHIKV infection due to their type I interferon production (discussed in section 1.2.4)72. More
careful characterization of infiltrating myeloid cells and their effector functions during CHIKV
infection will be valuable for clarifying these findings.
Natural killer (NK) cells also infiltrate into the joint and muscle tissues following CHIKV
infection52. Two separate studies have identified elevated NK cell percentage or activation in
PBMCs isolated from patients73,74. Careful evaluation of the function of NK cells during CHIKV
pathogenesis has not been done, but one study did note that NK cells mediated worse disease with
an East-Central-South-African (ECSA) genotype of CHIKV, but not with an Asian lineage of
CHIKV, suggesting that there might be strain-specific effects of NK cell involvement in
pathogenesis75. Another innate-like cell type often involved in skin immune responses is γδ T cells.
One study showed that TCRγδ-KO mice had worsened foot swelling at 7 dpi, accompanied with
elevated proinflammatory cytokines and altered cellular recruitment, but no change in viral load
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was observed76. This finding implies a protective immunomodulatory role for γδ T cells in CHIKV
infection. Innate lymphoid cells are involved in a number of acute inflammatory models, including
RA, but they have not been evaluated in CHIKV pathogenesis77.
Acute Pathogenesis: Adaptive Immune Responses
Adaptive immune responses are involved in both protection and pathogenesis during
CHIKV disease. Neutralizing antibodies are required for clearing infectious virus, whereas CD4 +
T cells play a critical role in promoting pathogenesis. This is demonstrated in Rag1-/- mice, which
fail to control viremia and sustain infectious virus replication in their periphery for greater than 3
months post infection54. Coincidentally, Rag1-/- animals are also largely protected from clinical
disease. Further characterization, of CD4-KO and CD8-KO mice determined that it was CD4+ T
cells contributing to pathogenesis and antibodies responsible for clearing virus, whereas CD8+ T
cells seem to be dispensable. Passively administering CHIKV neutralizing antibodies to Rag1-/mice eliminates infectious virus, but after administration was stopped, infectious virus re-emerged,
suggesting that neutralizing antibodies are able to control, but not clear CHIKV54,55. A pathogenic
role for CD4+ T cells is reinforced with the observation that expansion of T regulatory cells with
an IL-2/anti-IL-2 complex prior to CHIKV infection alleviated disease by inhibiting CHIKVspecific effector CD4+ T cells78. These findings from animal models are supported by a study of a
patient cohort, which found greater percentages of activated effector CD4+ and CD8+ T cells in
peripheral blood mononuclear cells (PBMCs) isolated from patients with persistent CHIKV
polyarthritis and patients with untreated, active rheumatoid arthritis (RA) compared to healthy
controls23. Taken altogether, there is profound evidence that adaptive immune responses play
important roles in the early stages of acute CHIKV disease.
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Chronic pathogenesis
It is known that CHIKV RNA, but not infectious virus, persists in the joints and
musculoskeletal tissues of patients and animals infected with various strains of CHIKV52,55,66.
Furthermore, mice infected with a CHIKV strain engineered to express firefly luciferase still
showed bioluminescence at chronic time points79. It is possible that this persistent RNA is
continuously stimulating an inflammatory response. Consistent with this theory, a number of IFNrelated and proinflammatory genes were upregulated in CHIKV-infected foot tissue at 30 dpi
compared to day 0 samples55. High levels of IFN-α was observed in PBMCs isolated from chronic
CHIKV patients, and another group found that persistent arthralgia was associated with elevated
levels of IL-6 and GM-CSF66,68. There is still much to be done to delineate the mechanisms of
chronic CHIKV pathogenesis.

1.2 Type I Interferons
1.2.1 Overview
Type I interferons (IFN-I) are a family of multifunctional cytokines originally named for
their ability to interfere with viral replication in vitro, and now they are recognized as major
effector cytokines with important roles in both innate and adaptive immune responses80,81. General
properties of IFN-I include eliciting an antiviral state through the induction of interferon stimulated
genes (ISGs) and modulating innate and adaptive immune responses through both direct and
indirect effects. IFN-I in mice consist of 14 IFN-α subtypes and single forms of IFN-β, IFN-ε,
IFN-κ, and IFN-ω. Despite signaling through a shared receptor and possessing a similar spectrum
of functions, in vitro studies and recent work in vivo highlight that there are different potencies of
shared functions and some unique properties among the individual subtypes. The multigene nature
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of IFN-I is conserved across many species, suggesting that having multiple IFN subtypes is
beneficial for the host.

1.2.2 Induction
Host cells possess many cell intrinsic and cell extrinsic mechanisms for detecting a viral
infection and coordinating an IFN-I response. Pattern recognition receptors (PRRs) detect
conserved pathogen-associated molecular patterns (PAMPs), such as nucleic acids during viral
infection82. The nucleic acid sensors can be found in the cytosol of many cell types or in specialized
endosomal compartments of immune cells and some nonhematopoietic cells83,84. Nucleic acidsensing PRRs are able to induce IFN-I through several distinct pathways, depending on the sensor
and cell type, but most pathways ultimately converge on the activation of IRF3 or IRF7
(summarized in Figure 1.3)82,85.
DNA Sensors
Cytosolic sensors of DNA include DNA-dependent activator of IFN-regulatory factors
(DAI)86 and cyclic GMP-AMP synthase (cGAS)87,88, whereas Toll-like receptor 9 (TLR9)
recognizes cytosine-guanosine motifs in DNA within endosomes89. Most cytosolic DNA sensor
signaling pathways converge on the activation of stimulator of IFN genes (STING), which is
located on the endoplasmic reticulum. Activation of STING results in the phosphorylation and
activation of TANK-binding kinase 1 (TBK1)90. TBK1 phosphorylates IRF3 or IRF7, allowing for
their translocation into the nucleus. In contrast, TLR9 signals through MyD88 (myeloid
differentiation primary response 88) to activate the E3 ubiquitin ligase TRAF6 (TNF receptor
associated factor 6). TRAF6 can then induce proinflammatory cytokines via the activation of NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) or induce type I IFN production
through IRF7 activation91.
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RNA Sensors
Cytosolic RNA sensors include retinoic acid-inducible gene I (RIG-I), which recognizes
short dsRNA and RNA with 5’ triphosphate ends and melanoma differentiation-associated protein
5 (MDA5), which detects long dsRNA91. TLR3 and TRL7/8 are located in endosomes and
recognize dsRNA and single-stranded RNA, respectively82. RIG-I and MDA5 signal through
mitochondrial antiviral-signaling protein (MAVS), which when associated with the mitochondria
leads to IFN-I induction via TBK1-mediated activation of IRF3/7, whereas when it is associated
with the peroxisome, it leads to induction of a distinct set of antiviral genes. TLR3 signals through
TRIF (TIR-domain-containing adapter-inducing interferon-β) to induce IFN-I downstream of
TBK1-mediated activation of IRF391.
IRF3 and IRF7
Initially, most cells respond to PRR signals to activate interferon regulatory factor 3 (IRF3),
which can act on the promoters of the IFN-β and IFN-α4 subtypes92,93. These initial IFN-I subtypes
signal in autocrine and paracrine means to modulate expression of ISGs that include antiviral
effector molecules and regulators that promote the antiviral response. IRF7 is among the
transcriptional regulators induced by the early IFN-I subtypes, and it participates in a positive
feedback loop that induces the other IFN-α subtypes, thus amplifying and diversifying the IFN-I
response (Figure 1.4)94,95. The central role of IRF7 in inducing the IFN-α subtypes is demonstrated
in IRF7 deficient mice, which fail to produce many of the IFN-α subtypes in response to viral
infection, including CHIKV64,96–98. A recent study from the laboratory of Jean-Laurent Casanova
identified a compound heterozygous null mutation in IRF7 in a patient who suffered from a lifethreatening primary influenza A infection99. The patient’s leukocytes and plasmacytoid DCs
(pDCs) produced very little type I and type III interferons and supported higher viral replication
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in response to influenza infection; however, IFN-β was still mildly induced in the patient’s
stimulated cells. Thus, IRF7 is a master regulator of IFN-I, particularly IFN-α subtypes, in both
mice and humans. An exception to this IRF7 paradigm is pDCs, which are specialized cells of the
immune system capable of producing large amounts of IFN-I during a viral infection100. Unlike
most other cell types, pDCs constitutively express IRF7, enabling them to produce large amounts
of IFN-α subtypes directly downstream of TLR7 or TLR9 signaling. The importance of pDCs for
production of IFN-I during an infection can depend on the route of infection (systemic versus
peripheral) and tropism of the virus101,102.

1.2.3 Signaling
All type I IFN subtypes bind to and signal through a shared heterodimeric IFN-α/β receptor
(IFNAR), which is composed of the subunits IFNAR1 and IFNAR2. IFNAR expression is fairly
ubiquitous, enabling most cell types to respond to IFN-I. Ligand binding of IFNAR induces a
conformational change in the receptor that causes auto-phosphorylation and activation of the
tyrosine kinases Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), which are constitutively
associated with IFNAR2 and IFNAR1, respectively103. Activated JAK1 and TYK2 then regulate
the phosphorylation and activation of various signal transducer and activator of transcription
(STAT) proteins104.
In canonical IFN-I signaling, STAT1 and STAT2 are phosphorylated and then form a
complex with IRF9. This complex is called the IFN-stimulated gene (ISG) factor 3 (ISGF3), which
can enter the nucleus and bind to IFN-sensitive response elements (ISREs) in the promoters of
ISGs104. Type I IFN signaling can also regulate genes downstream of type II IFN (IFN-γ) by
phosphorylating and activating STAT1 homodimers that bind to IFN-γ-activated site (GAS)
enhancer elements in the promoters of some ISGs105. Additional C-terminal serine phosphorylation
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of STAT1 and STAT2 is required for full transcriptional activation of ISGs but is not required for
STAT nuclear translocation or DNA binding106,107. Ultimately, IFN-I signaling culminates in
transcriptional regulation of hundreds of genes. These ISGs function to elicit an antiviral state in
infected and neighboring cells. IFN-I are also known to have immunomodulatory and pleiotropic
effects, depending on the cell type and context108.
There are many pathways independent of STAT activation that are induced upon IFN-I
stimulation, and these pathways play important roles in regulating the pleiotropic effects of IFNs.
In brief, TYK2-mediated phosphorylation of the scaffolding protein insulin receptor substrate 1
(IRS1) allows for activation of the PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase)
pathway, resulting in a broad range of biological effects including interleukin-10 (IL-10)
production and protein kinase C delta (PKC-δ) activation109,110. PKC-δ is thought to be important
in serine phosphorylation of STATs, as pharmacological inhibition of PI3K blocks STAT1
phosphorylation at Ser727 and reduces STAT1-dependent transcription111. TYK2 can also recruit
and phosphorylate the adaptor molecule CRKL (Crk-like protein), leading to the activation of the
p38 MAPK (mitogen-activated protein kinase) pathway, which is required for IFN-I-mediated
production of genes under ISRE and GAS regulation112.

1.2.4 IFN-I Induction during CHIKV Infection
CHIKV has evolved mechanisms to counteract IFN-I action, highlighting the importance
of IFN-I in combating CHIKV. CHIKV nsP2 translocates into the nucleus and degrades the host
RNA polymerase II subunit RPB1, which results in general host cell transcriptional shut-off and
cytopathic effects in mammalian cells113. Additionally, nsP2 is able to directly antagonize IFN-I
signaling by preventing phosphorylated STAT1 from entering the nucleus by mechanisms that are
still unclear114,115. Despite this antagonism, human patients infected with CHIKV mount a robust
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innate immune response, including the induction of IFN-I and other cytokines and chemokines,
and this is recapitulated in animal models56,58.
Nonhematopoietic Cells Induce IFN-I via MAVS
Most cells are able to produce IFN-I in vitro, but induction in vivo is more complicated.
One study generated a series of BMCs to characterize cell type-dependent PRR pathways
responsible for IFN-I induction in vivo97. IRF3/7 DKO mice fail to make sufficient IFN-I and
succumb to CHIKV infection with slightly delayed kinetics compared to IFNAR1-KO mice. DKO
 WT BMCs were able to survive infection and control viral dissemination, indicating a role for
nonhematopoietic cells in producing IFN-I during CHIKV infection. In vitro evidence indicated
that MAVS is critical for IFN-I induction in mouse embryonic fibroblasts (MEFs) following
CHIKV infection116. Although DKO  MAVS-/- BMCs survive infection, they showed enhanced
viremia and dissemination. In contrast, the viral loads in MAVS-/-  DKO BMCs were almost
identical to that of WT  DKO. These findings suggest that MAVS plays an antiviral role in
nonhematopoietic cells, but is less important for IFN-I responses in hematopoietic cells. An
antiviral role for MAVS pathways is further demonstrated in MAVS global knockout mice, which
develop more severe clinical disease and enhanced viral replication64,116. It is also worth noting
that RIG-I-/- or MDA5-/- mice do not show these clinical or virologic phenotypes, suggesting that
RIG-I and MDA5 have redundant roles in CHIKV infection.
Hematopoietic Cells Induce IFN-I
There is also evidence that immune cells can produce IFN-I during CHIKV infection. WT
 DKO BMCs were able to survive infection and only showed limited increase in viral
dissemination compared to WT  WT BMCs97. These results demonstrate that hematopoietic
cells can be a sufficient source of IFN-I to effectively control CHIKV infection. That same study
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performed multiple BMCs to determine the hematopoietic-specific PRR pathways responsible for
protecting DKO recipients that fail to induce sufficient IFN-I. TLR7-/-  DKO and MyD88-/- 
DKO BMCs survived infection and controlled viral replication similarly as WT  DKO BMCs.
This was surprising, given that MyD88-/- mice develop worse clinical disease and mildly worse
viral loads compared to WT mice64,116. These data suggest that hematopoietic cells induce
sufficient IFN-I for DKO recipients via a MyD88-independent pathway.
Several studies have characterized the role of TLR3 during CHIKV infection and found
conflicting results. One group reported increased viremia and worsened clinical disease,
characterized by severe infiltration of neutrophils and F4/80+ macrophages/monocytes in TRL3-/mice117. This group also generated TLR3-/-  WT BMCs which recapitulated the viremia in the
TLR3 global knockout mice, but showed no change in clinical disease. This suggests that TLR3
may have an antiviral role in immune cells and an anti-inflammatory role in nonhematopoietic
cells. Strikingly, a second group reported no virologic phenotype in TLR3-/- mice, but this
discrepancy could be due to differences in route of infection or the age of animals116. An antiviral
role for TLR3, is supported by the observation that TRIF-/- mice develop worse foot swelling and
viremia after CHIKV infection64. All together, these data suggest that in immune cells, TLR3 may
play an antiviral role by means of a MyD88-independent, TRIF-dependent pathway. There also
seems to be a role for MyD88 in nonhematopoietic cells that impacts clinical disease but not viral
load. These effects could be mediated downstream of IL-1β, which also signals via MyD88. More
work is needed to delineate the roles these PRR pathways in nonhematopoietic and immune cells
play in pathogenesis of CHIKV disease.
Recently, the laboratory of Tem Morrison demonstrated that monocytes play an important
role in limiting disease severity and viral dissemination during alphavirus infection72. This study
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made use of transgenic mice expressing the diphtheria toxin receptor (DTR) under the control of
CCR2 expression, to allow for specific deletion of CCR2+ cells, namely monocytes. Loss of
monocytes worsened clinical disease and viral loads following infection with a related alphavirus,
Ross River virus (RRV). Additionally, they generated CCR2-DTR  DKO BMCs and
demonstrated that monocytes are the critical immune cell for inducing protective IFN-I.
Unfortunately, they did not perform these same BMC experiments with CHIKV, but they did
demonstrate that depletion of monocytes also resulted in more severe clinical disease and viral
dissemination during CHIVK infection. Other work demonstrated that CHIKV is able to bind and
enter monocytes and induce IFN-I production, but ultimately yields a nonproductive infection
(discussed further in section 1.1.6)65. Together these data imply that similar to RRV infection,
monocytes may be an essential hematopoietic source of IFN-I during CHIKV infection, but more
work is needed to confirm this. This would be consistent with the observation that both human and
mouse pDCs stimulated with CHIKV in vitro produced very little IFN-I compared to stimulation
with poly I:C, an agonist of TLR3, or influenza A, suggesting that another cell type is likely
responsible for producing IFN-I116.

1.2.5 IFN-I Action during CHIKV Infection
IFN-I Signals on Nonhematopoietic Cells
Mice that lack IFNAR1, and thus all IFN-I activity, are extremely susceptible to CHIKV
and other alphavirus infections, indicating that IFN-I are critical host factors for controlling
CHIKV infection56,64,97,116,118–120. Loss of both IRF3 and IRF7 (DKO) fail to produce sufficient
IFN-I and die from uncontrolled CHIKV replication and hemorrhagic shock-like symptoms,
similar to what is observed in IFNAR1 deficient mice64. The kinetics of lethality are slightly
delayed in the DKO mice compared to the IFNAR1-KO phenotype, suggesting that other factors,
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such as IRF1 or IRF5, may also induce some IFN-I during CHIKV infection, though insufficient
to control infection. Another study generated reciprocal WT  IFNAR1-/- and IFNAR1-/-  WT
BMCs to determine the cell type-dependent IFNAR expression responsible for controlling CHIKV
infection116. They found that IFN-I signaling is required on nonhematopoietic cells to control
CHIKV infection. However, the authors did not evaluate pathogenesis or viral load, so there is
possibility of some involvement of IFN-I signaling on immune cells during CHIKV infection.
Altogether, these findings are unsurprising given that the cellular targets of CHIKV are primarily
nonhematopoietic cells, such as fibroblasts and muscle cells.
Functions of ISGs in CHIKV Infection
IFN-I ultimately exert their biological properties by inducing ISGs, but only a short list of
ISGs have been studied in the context of CHIKV infection. Viperin (encoded by the gene Rsad2)
was found to restrict CHIKV replication in vitro, and Rsad2-/- mice were more susceptible to
CHIKV infection121. Protein kinase R (PKR) transcription is regulated by both IFN-I signaling and
various stress responses, and then it requires activation by the presence of dsRNA. Once active,
PKR phosphorylates the eukaryotic translation initiation factor (eIF2α) to inhibit cellular mRNA
translation, but it can also indirectly aid in activation of multiple transcription factors, such as
STAT1122. Studies have demonstrated that PKR is activated during CHIKV infection in vitro,
which leads to the upregulation of several genes that promote IFN-I production, such as GADD34.
Cells lacking PKR or GADD34 supported increased CHIKV replication and induced very little
IFN-β123,124. Furthermore, neonatal mice lacking GADD34 were more susceptible to CHIKVinduced lethality compared to WT mice and supported higher viral loads in multiple tissues,
establishing important anti-CHIKV properties for PKR and GADD34 in vivo.
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Additionally, IFITM3 has been demonstrated to block CHIKV fusion in cells, and BST2
(also known as tetherin) has been shown to block CHIKV budding. Both IFITM3 and BST2 play
antiviral roles during CHIKV infection in vivo, as mice that lack either IFITM3 or BST2 displayed
worsened disease and higher viral replication in several tissues125–127. ISG15 is one of the most
rapidly and abundantly upregulated genes in response to IFN-I. It contains two ubiquitin-like
domains, and similar to ubiquitin, it can be conjugated to viral and host proteins128. ISG15-KO
neonatal mice are much more susceptible to CHIKV-induced lethality, but displayed similar viral
loads throughout infection. Rather than functioning to limit viral replication, as it does in several
other viral systems, the absence of ISG15 during neonatal CHIKV infection promoted a cytokine
storm phenotype58. Collectively these studies have begun to define the mechanistic basis for ISGmediated modulation of CHIKV replication and pathogenesis, but much work remains characterize
the roles of ISGs during CHIKV infection.
In summary, there has been substantial effort to characterize the pathways and cell types
that induce IFN-I during CHIKV infection, the cells that respond to IFN-I, and the mechanistic
actions of some ISGs. This collective work has yielded a model in which IFN-I signaling is
absolutely required on nonhematopoietic cells to control CHIKV infection. Both hematopoietic
cells, likely monocytes, and nonhematopoietic cells can produce sufficient IFN-I to control
CHIKV, though they utilize distinct pathways to do so. Hematopoietic cells likely utilize the
TLR3-TRIF pathway, whereas nonhematopoietic cells rely on the RIG-I/MDA5-MAVS
pathways. A central role for nonhematopoietic cells, like fibroblasts and muscle, for supporting
viral replication and coordinating immune responses sets CHIKV apart from other alphaviruses.
Related alphaviruses such as RRV, Sindbis virus (SINV), and Venezuelan equine encephalitis
virus (VEEV), as well as the flavivirus West Nile virus (WNV), are all able to infect and induce
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IFN-I production in dendritic cells118,129,130. Thus, CHIKV infection could serve as a unique model
to study IFN-I responses in nonhematopoietic cells.

1.2.6 IFN-I Subtypes: evidence for functional differences
IFN-I are pleiotropic cytokines with broad biological activities that include upregulating
cell-intrinsic antiviral defense mechanisms, modulating proinflammatory cytokine production, and
augmenting innate and adaptive cellular responses. Despite signaling through a single, shared
receptor, the IFN-I subtypes have been documented to have distinct properties both in vitro and in
vivo. Examples and mechanisms of these functional differences are discussed below.
Functional differences in vitro
All IFN-I subtypes bind to IFNAR, but with varying affinities. For example, IFN-α2 has
nanomolar binding affinity to IFNAR2 and micromolar affinity for IFNAR1, whereas IFN-β
exhibits picomolar binding affinity for IFNAR2 and nanomolar affinity for IFNAR1131,132.
Differences in binding affinities among the IFN subtypes manifest as differences in dissociation
constants. IFN-β has about a 100 second half-life in a ternary complex with both receptors, and
IFN-α2 has a half-life of about 1 to 5 seconds133,134. Careful mapping of structural and biochemistry
properties have revealed that for some IFN-I properties, such as antiproliferative activity, different
potencies among the subtypes are ascribed to differential binding affinities and dissociation rates
for the receptor. These properties that are highly dependent on cellular context and affinity are
designated as “tunable” IFN properties. For example, IFN-β has the highest known natural affinity
for IFNAR and has been shown to be the most potent inhibitor of osteoclastogenesis of monocytic
precursors in vitro135. In contrast, “robust” IFN-I properties, such as antiviral activity, only
marginally improve with increased affinity and are programmed for maximal output by all
subtypes irrespective of affinity or cellular context136. The ability of IFN-I signaling to have graded
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responses to multiple ligands likely contributes to the pleiotropic activities ascribed to IFN-I and
provides a molecular explanation for how IFN-I subtypes can have unique properties (summarized
in Figure 1.5).
Lessons from IFN-ε
Prior to 2013, the function of IFN-ε remained uncharacterized. A study published in
Science showed that unlike the other type I IFN subtypes, IFN-ε is not induced by Toll-like
receptor ligands. Rather, it is constitutively expressed by the epithelium of reproductive organs,
with its expression further regulated by sex hormones137. Likely a consequence of its unique
regulation, IFN-ε is the only type I IFN subtype shown to play a protective role against Chlamydia
infection, whereas the other subtypes may worsen disease137,138. IFN-ε signals through IFNAR like
the other IFN-I subtypes, but with some notable differences. A recent paper demonstrated that
unlike other studied IFN-I subtypes, IFN-ε displays higher affinity for the IFNAR1 subunit
compared to IFNAR2139. Additionally, IFN-ε was the only subtype shown to have cross-species
reactivity for human IFNAR, which had also been previously shown for canine IFN-ε140.
Collectively, these studies demonstrate that IFN-ε has distinct biological properties both in vitro
and in vivo, and these distinctions are relevant for human disease.
IFN-β deficient mice
Some of the first attempts to delineate properties of individual IFN-I subtypes in vivo came
with the generation of mice that specifically lack the IFN-β subtype141. IFN-β-KO mice are more
susceptible than wild type (WT) mice to West Nile virus (WNV), an encephalitic flavivirus142. The
increased lethality in the IFN-β-/- mice was accompanied with elevated viral replication in some,
but not all tissues. WNV was similarly controlled in the serum and spleen by IFN-β-KO and WT
mice, and consistent with this, IFN-I activity in the serum was comparable between the two
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genotypes. Onset of viral replication was similar in certain peripheral tissues, such as the central
nervous system (brain and spinal cord) and kidneys, but viral loads accumulated to higher levels
in the IFN-β deficient mice. This suggests that for some tissues, IFN-β functions to limit replication
within those tissues, but not the viral seeding of those tissues. In striking contrast, the lymph nodes
displayed very early and severely elevated replication, suggesting an early antiviral role of IFN-β
in select tissues. Furthermore, WNV infection of cell cultures generated from IFN-β-KO mice
revealed that macrophages and dendritic cells supported significantly higher WNV replication
compared to WT cells, whereas the phenotype was minimal or non-existent in cultured fibroblasts
and neurons, suggesting that there might be cell-type specificity for requirement of certain IFN-I
subtypes. Taken together, these data suggest that during WNV infection IFN-β has a protective,
antiviral role in limiting replication in certain cell types and tissues, and of note, the virologic
phenotype in IFN-β-KO mice was not as severe as what has been described for WNV infection in
mice lacking other components of the IFN-I system (Ifnar-/-, Irf3-/-, or Irf7-/- mice)96,130,143.
Several other studies have also identified a protective, antiviral role for IFN-β during viral
infection. One study demonstrated that IFN-β-KO mice were more susceptible to 3 different doses
of intranasal inoculation of vaccinia virus, a member of Poxviridae with a dsDNA genome144.
Similar to what was observed with WNV infection, only certain tissues displayed increased viral
loads, namely the lung and brain, but not the spleen. Another study demonstrated a protective role
for IFN-β in coxsackievirus B3 infection145. Coxsackievirus group B belong to the Picornaviridae
family of positive-sense, ssRNA viruses that cause viral myocarditis. When infected with
coxsackievirus B3, 70% of IFN-β-/- mice succumbed to infection by 5 dpi, whereas 100% of WT
mice survived. Interestingly, the viral loads at 4 dpi (just before lethality) were not different in the
heart and only slightly elevated in the liver and spleen in the IFN-β-KO mice; however, IFN-β26

KO mice did show increased inflammation and infiltrates by histology in the heart compared to
WT mice, suggesting that IFN-β might have protective antiviral and immunomodulatory functions
in this context.
One of the most intriguing and complicated viral systems to study IFN-I biology might be
influenza A (IAV) infection. Some studies have reported that IFN-I directly correlates with disease
severity, whereas other studies indicated that IFN-I inversely correlated with pathology146.
Pretreatment of mice with IFN 8 hours prior to infection protected mice from severe infection, but
only in mice that expressed the IAV-restricting ISG MX1147. In contrast, treatment of MX1negative mice with exogenous IFN-I increased morbidity and mortality during IAV infection by
upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)148. These
findings highlight that during IAV infection, IFN-I have a complex role, and whether they play a
beneficial or detrimental role may depend on the genetic background of the mouse, dose or route
of the inoculum, and concentration of IFN-I induced. C57BL/6 mice are MX1-negative and
susceptible to influenza infection. One study generated C57BL/6 mice that do express MX1 but
are deficient for IFN-β149. In this MX1-postive genetic background, IFN-β was shown to play a
protective antiviral role, as mice lacking IFN-β showed greater lethality and higher viral burden in
the lung following IAV infection. Taken altogether, the current model of IFN-I activity during
IAV infection is that moderate, transient expression of IFN-I induces a protective antiviral
response, whereas excessive or prolonged IFN-I induction is detrimental by exacerbating
inflammation.
IFN-α versus IFN-β during LCMV Infection
The lack of IFN-α deficient mice has hindered the direct functional comparison of IFN-α
versus IFN-β in vivo, but the recent development of blocking monoclonal antibodies (mAb)
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specific for either IFN-α or IFN-β is making those studies possible98. In a study with lymphocytic
choriomeningitis virus (LCMV) persistent infection (clone 13), Oldstone and colleagues
demonstrated that IFN-β is dispensable for controlling early LCMV replication and spread,
suggesting that other subtypes, such as the IFN-α’s, are the dominant subtypes contributing to the
antiviral responses. Indeed, blockade of IFN-α worsened viral loads. In contrast, IFN-β was found
to be detrimental to the host and responsible for promoting LCMV persistence150. Specific
blockade of IFN-β improved antiviral T cell responses that led to accelerated virus clearance,
recapitulating what is observed with blockade of IFNAR1 during LCMV infection151,152. Infection
of dendritic cells is an important step for establishment of persistent LCMV infection, and mice
that were treated with anti-IFNAR1 or anti-IFN-β mAb showed decreased infection of CD8α–
dendritic cells, suggesting a mechanism for viral clearance. Whereas studies have been performed
to assess the specific role of the IFN-β subtype, this was the first report to directly compare the
properties of IFN-α and FIN-β and observe distinguishable biological functions.
Collectively, these studies highlight that cellular source, timing, concentration, and context
of expression can drastically impact the function of an IFN-I subtype. IFN-I are both the targets of
and used as therapeutics for a number of diseases, such as hepatitis C infection, multiple sclerosis,
and some cancers, and careful study of the functions of individual subtypes may lead to more
effective treatments with less off-target effects153.
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1.3 Figures

Figure 1.1 Replication cycle of CHIKV in mammalian cells
This figure was taken from Silva, L. A. & Dermody, T. S. Chikungunya virus: epidemiology, replication,
disease mechanisms, and prospective intervention strategies. J. Clin. Invest. 127, 737–749 (2017). In brief,
CHIKV replication in mammalian cells is characterized by i-iii) receptor-mediated endocytosis and pHdependent fusion, iv-v) early replication of negative-strand genome occurs in spherules, vi-viii) formation
of large cytopathic vacuoles (CPV-I) where subgenomic and genomic RNA are transcribed and translated,
resulting in accumulation of nucleocapsids and E1/E2 dimers at the cell surface, and x-xi) nucleocapsids
associate with internalized E1/E2 spikes (CPV-II) to form mature virions, which egress and bud from the
cell.
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Figure 1.2 Summary of CHIKV pathogenesis in WT mice
This figure was taken from Fox, J. M. & Diamond, M. S. Immune-Mediated Protection and Pathogenesis
of Chikungunya Virus. J. Immunol. 197, 4210–4218 (2016). Infection of WT mice with CHIKV in the foot
produces a biphasic swelling response that is accompanied with histological signs of arthritis, myositis, and
synovitis. The first peak of foot swelling at 2-3 dpi is thought to arise from robust viral replication which
drives cell death, local proinflammatory cytokine production, and edema (box 1). The second peak at 6-7
dpi occurs as infectious virus is cleared from the tissues and blood and is associated with an influx of
inflammatory infiltrates into the joint spaces and surrounding soft tissues that drive cytokine production,
synovitis, myositis, and edema (box 2).
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Figure 1.3 Summary of pathways of IFN-I induction and signaling
This figure was taken from McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O’Garra, A. Type I
interferons in infectious disease. Nat. Rev. Immunol. 15, 87–103 (2015). Briefly, pattern recognition
receptor signaling pathways converge on the activation of IRF3 and/or IRF7 to induce IFN-I production.
IFN-I then exert pleiotropic effects by signaling through IFNAR to induce various JAK/STAT signaling
pathways and IFN-stimulated genes (ISGs). IFN-I can also activate other pathways, such as PI3K and
MAPKs.
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Figure 1.4 IRF7 participates in a forward feedback loop for IFN-I amplification
This figure was taken from Honda, K. & Taniguchi, T. IRFs: master regulators of signalling by Toll-like
receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6, 644–658 (2006). In the early
phase of IFN-I induction, IRF3 (or IRF7 in some cells, such as pDCs) acts on the promoter of IFN-β (and
IFN-α4, not depicted). Secreted IFN-I signals through IFNAR to upregulate IRF7, which can then bind the
promoters of the other IFN-α subtupes, as well as IFN-β, to amplify the IFN-I response.
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Figure 1.5 Molecular basis for functional differences among IFN-I subtypes
This figure was taken from Schreiber, G. & Piehler, J. The molecular basis for functional plasticity in type
I interferon signaling. Trends Immunol. 36, 139–149 (2015). Upper panel: The affinities (KD) for each
receptor subunit and EC50 values for antiviral and antiproliferative activities are listed for three natural IFNI subtypes (IFN-α1, IFN-α2, and IFN-β) and two engineered IFN-α mutants (YNS and IFN-1ant). Lower
panel: Some IFN-I properties are “robust” and do not correlate with affiinty to the receptor, whereas
“tunable” IFN-I properties require longer or continuous activation of the receptor, display a linear
correlation with affinity for the receptor, and may be cell type specific.
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Chapter 2
Interferons alpha and beta protect against chikungunya
virus pathogenesis by distinct mechanisms of action

This chapter contains data from a manuscript in preparation for submission.
L. E. Cook, M. C. Locke, A. R. Young, K. Monte, M. L. Hedberg, R. M. Shimak, D. J. Veiss,
M. S. Diamond, D. J. Lenschow. Interferon alpha limits chikungunya virus replication, but not
interferon beta, which controls immunopathology mediated by neutrophils. (2018).
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2.1 Abstract
Type I interferons (IFN-I) possess a wide range of biological activity and are important in
protection against a number of viruses, including alphaviruses. Despite signaling through a shared
receptor, there are well documented biochemical and functional differences among the different
IFN-I subtypes. Work with lymphocytic choriomeningitis virus (LCMV) persistent infection
previously demonstrated that IFN-α and IFN-β have distinguishable biological activities, with
IFN-α functioning to limit viral replication and IFN-β playing a detrimental role by promoting
persistent infection. Herein, we demonstrate that IFN-α and IFN-β both play protective roles
during acute CHIKV infection, but they do so by distinct mechanisms. IFN-α limits CHIKV
replication and dissemination, but in contrast, IFN-β protects from CHIKV pathogenesis by
limiting immunopathology mediated by neutrophils. Our findings support the accumulating
evidence that the IFN-I subtypes have distinct biological activities, and we identify a novel
mechanism for the differential activity of IFN-β compared to the IFN-α’s.

2.2 Introduction
Type I interferons (IFN-I) are a family of multifunctional cytokines, and in mice they
consist of 14 IFN-α subtypes and single forms of IFN-β, IFN-ε, IFN-κ, and IFN-ω. Their broad
pleiotropic properties include upregulating cell-intrinsic antiviral defense mechanisms,
modulating proinflammatory cytokine production, and augmenting innate and adaptive cellular
responses. All IFN-I exert their effects by binding to the shared heterodimeric IFN-α/β receptor
(IFNAR), which is composed of the subunits IFNAR1 and IFNAR2. Engaging IFNAR activates
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signaling programs
to modulate the expression of hundreds of interferon stimulated genes (ISGs)104. Conservation of
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the IFN-I family’s multigene nature across many species suggests that expression of multiple IFN
subtypes is beneficial for the host defense. However, the physiological roles of the individual
subtypes remain poorly understood.
IFN-I are rapidly induced in response to infection with viruses and other pathogens. Host
pattern recognition receptors (PRR) that recognize nucleic acids are important sensors of viral
infection. For many cells, the immediate response to PRR signaling leads to the production of IFNβ and IFN-α4 subtypes via activation of interferon regulatory factor 3 (IRF3). These initial IFN-I
subtypes signal in autocrine and paracrine means to modulate expression of ISGs that include
antiviral effector and regulator molecules. IRF7 is among the transcriptional regulators induced by
the early IFN-I subtypes, and it participates in a positive feedback loop that induces the other IFNα subtypes, thus amplifying and diversifying the IFN-I response85,94,95. The central role of IRF7 in
inducing the IFN-α subtypes is demonstrated in IRF7 deficient mice, which fail to produce many
of the IFN-α subtypes in response to viral infection64,96–98.
Despite possessing a similar spectrum of activities, the IFN-I subtypes display unique
properties and different potencies of shared functions. Structural and biochemistry studies have
ascribed these distinct properties to differential binding affinities and dissociation rates for the
IFN-I receptor154–157. The ability of IFNAR to have graded responses to multiple ligands likely
contributes to the wide range of biological activity documented for IFN-I, but until recently, the
physiological relevance of these biochemical differences was unclear. In a study with lymphocytic
choriomeningitis virus (LCMV) persistent infection, Oldstone and colleagues demonstrated that
IFN-β is dispensable for controlling LCMV replication and spread, suggesting that other subtypes,
such as the IFN-α’s, are the dominant subtypes contributing to the antiviral response. Instead, IFNβ was found to be detrimental to the host and responsible for promoting LCMV persistence.
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Specific blockade of IFN-β improved antiviral T cell responses that lead to accelerated virus
clearance, recapitulating what is observed with blockade of IFNAR1 during LCMV infection150–
152

. Infection of dendritic cells is an important step for establishment of persistent LCMV infection,

and mice that were treated with anti-IFNAR or anti-IFN-β mAb showed decreased infection of
CD8α– dendritic cells, suggesting a mechanism for viral clearance. Taken together, the
biochemical evidence and work with LCMV demonstrate that IFN-α’s and IFN-β have
distinguishable biological activities and that these differences can have profound implications for
viral pathogenesis.
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus capable of causing
explosive outbreaks of acute fever, rash, polyarthritis, arthralgia, and myositis2,8. These symptoms
reflect an interplay between extensive viral replication and damage mediated by immune cells,
such as macrophages and activated CD4+ T cells51,53,79. However, not all immune responses are
detrimental. Neutralizing antibodies and IFN-I have been shown to be important in controlling
CHIKV infection, and mice that lack IFNAR rapidly succumb to infection due to hemorrhagic
shock and uncontrolled virus dissemination17,64. Despite their central role in limiting alphavirus
infection, little is known about the contributions of individual IFN-I subtypes to protection against
CHIKV infection. To explore this question we used genetic deletion mutants and antibody
blockade to determine the contributions of IFN-α and IFN-β during acute CHIKV infection. Both
IFN-α and IFN-β protect the host during acute CHIKV infection. However, our findings suggest
distinct roles for the IFN-I subtypes during CHIKV infection, with IFN-α limiting early viral
replication and spread and IFN-β controlling neutrophil-mediated immunopathology. Thus, these
results define a novel mechanism by which IFN-β can have distinguishable biological activity from
the IFN-α’s.
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2.3 Results
IFN-α and IFN-β both play protective roles in limiting clinical CHIKV disease. Human
patients and mice infected with CHIKV mount a robust innate immune response, including the
induction of IFN-I and other cytokines and chemokines56,58. Loss of IFNAR1 in mice leads to
uncontrolled viral replication and dissemination, with mice succumbing to infection by 3-4 days
post infection (dpi) from hemorrhagic shock-like symptoms56,58,64. Evidence shows that the IFN-I
subtypes have distinct biological properties, but there have been no studies performed to determine
the roles of individual subtypes in CHIKV pathogenesis.
To address this, we evaluated the pathogenesis of CHIKV in wild type C57BL/6J (WT),
IFN-β knockout (KO), and IRF7-KO mice. IRF7-KO mice have previously been shown to lose
IFN-α amplification during CHIKV infection with minimal impact on IFN-β production64.
Animals were infected subcutaneously in the left rear foot with 103 plaque forming units (PFU) of
a clinical isolate of CHIKV (La Réunion, 2006) and monitored daily for clinical foot swelling.
Previous studies have described a biphasic swelling response in the CHIKV-infected foot of WT
mice, with a first peak usually observed 2-3 dpi and a second, larger peak at 6-7 dpi. Mice that
lack IFN-β developed much more severe foot swelling that mimics the kinetics of swelling seen
in WT mice (Fig. 2.1A, p < 0.0001). In contrast, mice that lack IRF7 develop a large initial peak
of swelling at 3 dpi and a delayed second peak at 11 dpi (Fig. 2.1A, p < 0.0001). Both IFN-β-KO
and IRF7-KO mice also displayed prolonged foot swelling out to at least 15 dpi compared to WT
mice, which typically clear swelling by about 12 dpi (Fig. 2.1A). These data highlight that IFN-β
and IFN-α both play important protective roles to limit clinical disease during CHIKV infection,
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but the differences in the kinetics of swelling between the IFN-β-KO and IRF7-KO mice suggest
that different mechanisms may underlie these phenotypes.
Though IRF7 has previously been shown to play a critical role in IFN-α production, it is
also known to regulate a number of antiviral genes independent of IFN production, for example
tetherin (also known as BST-2 or CD317)158. Therefore, to evaluate if the phenotype in IRF7
deficient mice was due to loss of IFN-α, we made use of a pan-IFN-α blocking antibody (TIF3C5) and an IFN-β specific blocking antibody (HDβ-4A7) to more directly assess the impact of
the IFN subtypes on CHIKV pathogenesis98,150. WT mice were treated with the blocking antibodies
one day before and again one day after CHIKV infection and monitored for foot swelling in the
ipsilateral foot. Monoclonal antibody (mAb) blockade of IFN-α or IFN-β mimicked the early
swelling trends observed in the IRF7 and IFN-β deficient mice, respectively. At 3 dpi, both the
IFN-α and IFN-β mAb blockade groups displayed an increase in foot swelling compared to the
isotype control treated group (Fig. 2.1B, p < 0.0001). However, the foot swelling at later acute
time points (7-14 dpi) in the IFN-I blockade groups were less severe than the genetic deletion
models, which could be due to the limited dosing regimen or partial blockade. These data confirm
that the early foot swelling phenotypes in IFN-β-KO and IRF7-KO mice are due to loss of IFN-β
and IFN-α, respectively. Taken together, these results suggest that IFN-β and IFN-α have distinct,
non-redundant roles in protection from CHIKV clinical disease.
IFN-β-KO, but not IRF7-KO, mice have increased cellular infiltration into the
midfoot joint spaces during acute CHIKV infection. In a WT mouse, the first peak of foot
swelling (2-3 dpi) is thought to arise from robust viral replication which drives cell death, local
proinflammatory cytokine production, and edema. The second peak (6-7 dpi) occurs as infectious
virus is cleared from the tissues and blood and is associated with an influx of inflammatory
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infiltrates into the joint spaces and surrounding soft tissues that drive cytokine production,
synovitis, myositis, and edema51,53,55,79. To determine if the increased foot swelling observed with
loss of IFN-α or IFN-β was associated with worsened arthritis and inflammation, we next evaluated
histological sections for overall inflammation of the joints and musculoskeletal tissues in the
ipsilateral foot of WT, IFN-β-KO, and IRF7-KO mice at 7 dpi infection in a blinded manner. We
found that 100% of the IFN-β-KO mice showed severe inflammation (score of 3) in the infected
foot, whereas there was more variability in the severity of inflammation in the WT and IRF7-KO
mice (Fig 2.2A and 2.2C). Additionally, IFN-β-KO mice, but not IRF7-KO mice, showed
increased cellular infiltration into the midfoot joint spaces at 7 dpi compared to WT mice (Fig.
2.2D, p < 0.01). These data demonstrate that while both IFN-β-KO and IRF7-KO mice develop
severe CHIKV-induced foot swelling, only the IFN-β-KO mice appear to show increased
pathology, especially as measured by cellular infiltration into the mid-foot joint spaces.
IFN-α, but not IFN-β, limits CHIKV replication and dissemination. To further
investigate the differential roles of IFN-α and IFN-β, we next determined the infectious viral load
in the ipsilateral foot and distal tissues at varies times post infection by plaque assay. Analysis of
the ipsilateral foot revealed that mice lacking IFN-β supported CHIKV replication at similar levels
as WT mice (Fig. 2.3A). Clearance of infectious virus was similar between WT and IFN-β-KO
mice, with detectable virus cleared from both strains by 10 dpi (Fig. 2.3A). In contrast, mice
lacking IRF7 had 1 log10 higher CHIKV viral load in the ipsilateral foot at 2 and 3 dpi compared
to WT mice (Fig. 2.3A, p < 0.01) and had delayed clearance of infectious virus compared to WT
or IFN-β-KO mice, with 2 log10 more infectious virus at 7 dpi (Fig. 2.3A, p < 0.001).
We next evaluated the impact of loss of IFN-β or IRF7 on CHIKV dissemination to distant
tissues. Overall, we observed minimal difference between WT and IFN-β-KO mice in viral titers
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in several disseminated tissues. CHIKV titers in the serum of IFN-β-KO mice were the same as
WT mice at all time points examined. Likewise, we observed no difference in the time of onset of
replication in the distant tissues of IFN-β-KO mice, and only in the muscle did we observe a
significant change in the overall magnitude of viral replication compared to WT mice at 3 dpi (Fig.
2.3A, p < 0.0001). Conversely, IRF7-KO mice displayed a substantial increase in CHIKV
dissemination. IRF7-KO mice had substantially higher and prolonged viremia compared to WT
and IFN-β-KO mice, with 2 log10 more virus at 2 dpi and a 5 log10 increase at 3 dpi in the serum
(Fig. 2.3A, p < 0.0001). Additionally, CHIKV spread to distant sites much more quickly and
sustained elevated viral loads in IRF7-KO mice compared to WT mice. For example, IRF7-KO
contralateral ankles rapidly develop a 3 log10 increase in replication at 2 dpi, at a time when
replication is only just detectable in WT and IFN-β-KO mice. Additionally, whereas IFN-β-KO
and WT mice have cleared CHIKV from the opposite ankle at 7 dpi, there is still 104.5 pfu of virus
present in the IRF7-KO mice. These data suggest that IFN-β is dispensable for controlling CHIKV
replication and spread, and that other IFN-I subtypes, such as the IFN-α’s, are the dominant
subtypes eliciting antiviral responses.
Administering mAb blockade of either pan-IFN-α or IFN-β recapitulated the virologic
phenotypes we observed in the genetic knockout models. Blockade of IFN-β in WT mice had
minimal impact on viral load in the ipsilateral foot or in distal sites compared to mice treated with
an isotype control mAb (Fig. 2.3B). Treatment of WT mice with the IFN-α blocking mAb resulted
in an elevated viral load in the inoculated ankle at 7 dpi, more severe viremia, and a substantial
increase in dissemination to the muscle and distal joints, similar to what we observed in IRF7
deficient mice (Fig. 2.3B). These data suggest that IFN-α is important for controlling early viral
replication and spread, whereas IFN-β is dispensable for these effects. In contrast, the absence of
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IFN-β led to increased foot swelling and increased inflammatory cell infiltrates into the joint
spaces without impacting viral loads, suggesting that IFN-β may primarily function as an
immunomodulatory molecule during CHIKV. Taken together, these findings demonstrate that
IFN-α and IFN-β are both protective during CHIKV infection but mediate their effects by distinct
mechanisms of actions.
IFN-α and IFN-β exert their protective effects during CHIKV arthritis by signaling
on nonhematopoietic cells. Previous studies using bone marrow chimeras have demonstrated that
IFN signaling is required in nonhematopoietic cells to survive CHIKV infection116. However, these
studies evaluated only survival and did not determine the impact of IFN-I signaling on
immunopathology in the CHIKV arthritis model. To address this question, we utilized Vav-Cre
transgenic mice crossed onto the IFNAR1flox/flox background, which removes IFN-I signaling from
immune cells and endothelial cells159. Infecting Vav-Cre positive mice with 103 pfu CHIKV in the
footpad resulted in no lethality and did not yield any significant difference in clinical disease, as
measured by foot swelling, compared to Cre negative littermate controls (Fig. 2.4A). To determine
if loss of IFN-I signaling in hematopoietic cells impacts the ability to control viral replication or
spread, we assessed the viral load in the ipsilateral foot and distant tissues at several times post
infection. We did not observe significant differences in viral replication in the ipsilateral ankle or
distant tissues, though there was a slight delay in clearance of CHIKV from the serum (Fig. 2.4B,
p < 0.05). Taken together, these data suggest that IFN-α and IFN-β mainly signal on
nonhematopoietic cells to exert their respective protective effects during CHIKV arthritis.
IFN-β deficient mice have increased neutrophil recruitment into the ipsilateral foot
during CHIKV infection. Mice lacking IFN-β begin to develop increased foot swelling by 2 dpi,
but tissues support a similar level of CHIKV replication (Fig. 2.1-2.3). This led us to hypothesize
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that IFN-β protects from CHIKV pathogenesis by modulating the innate immune response.
Therefore, we first sought to determine how the absence of IFN-β affected early (2-3 dpi) cellular
recruitment into the ipsilateral foot tissue. Previous studies have demonstrated that macrophages,
monocytes, and neutrophils are among the early cells recruited to the infected foot and that altering
the balance of these infiltrating cells can drastically impact disease51,52,71,72. To quantitate
differences in immune cell infiltration into the foot, infected WT or IFN-β-KO mice were
sacrificed at 2 or 3 dpi, and the infected foot was disarticulated and digested to generate a single
cell suspension23. We stained the cell suspension for various surface cell identifying markers and
analyzed the cells were analyze by flow cytometry to determine the total number of immune cells
(CD45+), inflammatory monocytes (Ly6C+ CD11b+ Ly6G-), neutrophils (Ly6G+ CD11b+), and
macrophages (F4/80+ MERTK+) (fig. S2.1). At 2 dpi, we observed an increase in the total number
of neutrophils (4-fold), as well as a significant increase in the percentage of neutrophils among
CD45+ immune cells in mice lacking IFN-β compared to WT mice (Figure 2.5A, p < 0.05 and p <
0.0001). By 3 dpi, there was no longer a difference in neutrophil number, though there was still an
increase in percentage of neutrophils at this time point (Fig. 2.5A, p < 0.0001). We did not observe
a difference in total number of CD45+ cells, monocytes, or macrophages between WT and IFN-β
KO mice, but we did see a minor decrease in the percentage of monocytes at 2 dpi (Fig. 2.5A, p <
0.05). Consistent with the histological observations, these results suggest that IFN-β functions to
limit immunopathology during CHIKV infection by modulating neutrophil infiltration into the
ipsilateral foot.
Mice lacking IFN-β have increased early IL-9 levels in the ipsilateral foot. We next
assessed local cytokine and chemokine levels to determine the basis for increased neutrophil
recruitment in the infected feet of IFN-β-KO mice. Using a multiplexed assay, we measured
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cytokine and chemokine levels in the ipsilateral foot at 2 and 3 dpi in WT and IFN-β-KO animals.
We did not observe elevated proinflammatory cytokines, such as IL-6, IL-1β, or TNF-α, or
common neutrophil chemoattractants, such as CXCL1 (KC) or CXCL2 (MIP-2) in the IFN-β-KO
mice. In a panel of 25 cytokines and chemokines the only analyte significantly elevated in IFN-βKO foot tissue was IL-9 at 2 dpi (Fig. 2.6, p < 0.0001). Previous studies have shown that IL-9 can
contribute to acute inflammation in certain models including rheumatoid arthritis160. Importantly,
IL-9 has been linked to neutrophil survival and function in a model of arthritis, and furthermore,
in the context of experimental autoimmune uveoretinitis (EAU), treatment with IFN-β inhibited
IL-9 production by splenocytes161,162. Thus, elevated IL-9 points to a potential mechanism for
increased neutrophil numbers present in the IFN-β-KO mice.
Depletion of neutrophils alleviates the increased foot swelling seen in CHIKV-infected
IFN-β-KO mice, but not in IRF7-KO mice. Because we observed an increase in number and
percentage of infiltrating neutrophils in the infected foot of IFN-β KO mice at 2 and 3 dpi, which
correlates with when we first begin to see differences in clinical disease, we sought to determine
if neutrophils are responsible for the increased clinical disease severity in the IFN-β KO. We
depleted neutrophils by intraperitoneal administration of anti-Ly6G mAb (clone 1A8) one day
before infection and every other day through 7 dpi in WT, IFN-β-KO, and IRF7-KO mice.
Neutrophil depletion was confirmed by flow cytometric analysis of the blood 6 or 8 dpi (data not
shown). Neutrophil depletion had no effect on foot swelling in WT or IRF7-KO mice, but it
alleviated the increased foot swelling observed in the IFN-β-KO mice to WT levels. The beneficial
effects of neutrophil depletion began at 2 dpi in the IFN-β-KO mice (Fig. 2.7, p < 0.01), and this
protective effect persisted throughout the course of acute infection. Importantly, neutrophil
depletion had no effect on foot swelling in IRF7-KO mice, highlighting that distinct mechanisms
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are driving pathology in IFN-β-KO versus IRF7-KO mice (Fig. 2.7). This observation
demonstrates that neutrophils are required for exacerbated CHIKV clinical disease in the IFN-β
deficient mice.

2.4 Discussion
IFN-I signaling is critical for the protection against a number of RNA and DNA viruses.
Most of what is known about IFN-I biology comes from in vitro studies or the use of animals that
lack all IFN-I signaling through IFNAR1 deletion. Neither of these approaches have allowed
delineation of the roles of individual IFN-I subtypes in physiological context. Recent work with
lymphocytic choriomeningitis virus (LCMV) persistent infection demonstrated that IFN-α and
IFN-β have unique and distinguishable biologic functions, with IFN-β being mainly responsible
for promoting viral persistence150. Blockade of IFN-β during LCMV infection improved antiviral
T cell responses and ultimately decreased infection of CD8α– dendritic cells (DCs) at later time
points. In this study we show that both IFN-α and IFN-β play distinct protective roles during acute
CHIKV infection. We demonstrate that the IFN-α subtypes are sufficient for limiting viral CHIKV
replication and spread, whereas IFN-β is dispensable for controlling viral replication and instead
primarily functions to limit immunopathology by an apparent novel mechanism.
We demonstrate that the loss of IFN-α by mAb blockade or deletion of IRF7 increased
CHIKV replication and dissemination to distant tissues, supporting an important antiviral role for
the IFN-α’s during CHIKV infection. Previous work showed that during LCMV infection
blockade of IFN-α led to increased viral loads late in infection150. Similarly, IRF7-KO mice
infected with West Nile virus (WNV), an encephalitic flavivirus also transmitted my mosquitoes,
showed increased lethality compared to WT mice, and increased susceptibility was associated with
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lowered IFN-α induction and severe viral dissemination96,98. WNV and Dengue virus (DENV),
another encephalitic flavivirus, both require IFN-I signaling on hematopoietic cells to control
infection130,163; however, our findings demonstrate that the antiviral effects of the IFN-α’s during
CHIKV infection are primarily through their action on nonhematopoietic cells (Fig. 2.4). This is
supported by previous bone marrow chimera studies that demonstrated that IFN signaling is
required in nonhematopoietic cells to survive CHIKV infection116. Detailed characterization of
CHIKV tropism in Ifnar1-/- mice compared to WT mice in the arthritis model has not been done;
however, IRF3/IRF7 double KO (DKO) mice, which closely resemble the phenotype of IFNAR1KO mice during CHIKV infection, have been evaluated. DKO mice showed increased CHIKV
RNA staining of many similar cell types as WT mice in the ipsilateral foot, but also showed spread
to the epidermis, presumably due to infection of keratinocytes, which was not observed in WT
mice64. This is in contrast with what has been observed with loss of IFN-I during other alphavirus
infections. IFANR1 deletion during infection with a related alphavirus, Sindbis virus (SINV),
permitted infection of macrophage-DC-like cells, which normally restrict SINV infection in WT
mice118. Furthermore, related alphaviruses Ross River virus (RRV), SINV, and Venezuelan equine
encephalitis virus (VEEV) are all able to infect and induce IFN-I production in DCs, whereas this
has not been observed for CHIKV61,118,129,130. The reason for these differences is not fully
understood, but it may depend on the receptors or co-receptors for CHIKV entry, which still have
not been identified. So while IFN-I, particularly the IFN-α’s, appear to play important antiviral
roles in multiple viral infections, the cell types involved in these protective pathways are different
depending on the context.
Nonhematopoietic cells that are likely important for CHIKV pathogenesis include synovial
and skin fibroblasts and various muscle cell types, which have all been shown to support robust
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CHIKV replication56,61,64. There have been surprisingly few studies performed to determine how
these cell types contribute to CHIKV pathogenesis. There is accumulating evidence that stromal
cells participate in coordinating immune responses during various disease states, such as
rheumatoid arthritis (RA)164. Synovial fibroblasts are the main stromal cells of the synovium, and
they are responsible for producing the extracellular matrix (ECM) component of synovial fluid
and maintaining lubrication of the joint. Cultured human fibroblast-like synoviocytes from RA
patients were shown to express TLR3, TLR7, RIG-I, and MDA5, and consequently, stimulation
with polyinosinic-polycytidylic acid (poly I:C) induced IRF3 activation and IFN-I production165.
CHIKV can infect myoblasts, and certain strains, including La Réunion, are able to infect
myofibers7. Muscle cells are able to participate in innate immune responses, as IL-1β was shown
to induce nitric oxide synthase 2 (NOS2 or iNOS) in rat skeletal myoblasts, and human skeletal
muscle biopsies showed a linear correlation between IL-1β levels and iNOS expression166.
Keratinocytes are infected by many arboviruses, including WNV and DENV167,168; however,
human keratinocytes are refractory to CHIKV infection at a post-fusion step but are still able to
produce cytokines and IFN-I following CHIKV exposure, suggesting that they also might be an
important contributor to inflammation during CHIKV infection62. Extensive in vitro work has
demonstrated that different cell types can differentially respond to IFN-I signaling157. Clearly,
nonhematopoietic cells represent important responders to IFN-I during CHIKV infection in vivo,
and much more work is needed to characterize the cell type-specific protective antiviral ISGs and
proinflammatory pathways that are induced in these cells in response to CHIKV infection and IFNI signaling.
Whereas IFN-α was important for limiting viral replication, we demonstrate that loss of
IFN-β exacerbates acute CHIKV disease but without having much impact on viral loads at the site
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of inoculation or in distant tissues, suggesting that IFN-β primarily functions as a beneficial
immunomodulatory molecule. This is distinct from what was observed with LCMV infection,
where IFN-β was also dispensable for controlling viral replication but ultimately played a
detrimental role for the host and promoted LCMV persistence150. In that study, specific blockade
of IFN-β improved antiviral T cell responses and led to accelerated virus clearance, presumably
through decreased infection of CD8α– dendritic cells, suggesting that IFN-β likely signals on
DCs150,169. Additionally, IFN-β has well described beneficial immunomodulatory activity in the
treatment of multiple sclerosis and its mouse model, experimental autoimmune encephalomyelitis
(EAE), and in that context, IFN-I signaling was required in myeloid cells to exert protective effects
and limit autoimmunity170,171. In contrast, we demonstrate that IFN-β is protective in CHIKV
infection by signaling on nonhematopoietic cells and ultimately limits neutrophil recruitment into
the site of inflammation (Fig. 2.4 and 2.5). Furthermore, depletion of neutrophils completely
reversed the exacerbation of clinical CHIKV disease seen in the IFN-β-KO mice. Dysregulated
neutrophil recruitment has been previously documented to increase acute CHIKV disease severity.
Mice deficient for the chemokine (C-C motif) receptor 2 (CCR2) or Toll-like receptor 3 (TLR3)
both developed more severe and prolonged CHIKV arthritis associated with early and severe
neutrophil infiltration71,117. Increased neutrophil recruitment in the CCR2-KO mice was
accompanied with increased expression of inflammatory mediators. However, we were surprised
to see unaltered, or even slightly lowered, levels of many proinflammatory cytokines and
chemokines in the ipsilateral foot tissue of IFN-β-KO mice, including the known neutrophilattracting chemokines CXCL1 (KC) and CXCL2 (MIP-2α)71. Unexpectedly, IL-9 was the only
significantly altered cytokine out of 25 tested analytes by multiplex assay (Fig. 2.6). More work
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needs to be done to determine if IL-9 is directly involved in the worsened CHIKV disease of IFNβ-KO mice.
IL-9 is generally described as a type 2 immunity cytokine, and as such, it has a protective
role during helminth infections; however, it has also been shown to contribute to pathogenesis
during autoimmune inflammation, such as rheumatoid arthritis and allergic responses160,172.
Despite being originally characterized as a T cell cytokine, an IL-9 fate reporter mouse revealed
that type 2 innate lymphoid cells (ILC2s) are the predominant source of IL-9 during a lung
inflammation model173. We observed elevated IL-9 prior to the generation adaptive immune
responses (2 dpi), which suggests that ILC2s are a potential source of IL-9 in the IFN-β-KO mice.
ILC2s are known to produce IL-9 when they are stimulated with IL-25, IL-33, and thymic stromal
lymphopoietin (TSLP), which are typically secreted by damaged epithelium barriers174. Synovial
fibroblasts isolated from RA patients have been shown to produce both IL-33 and TSLP175,176.
Unfortunately, these cytokines were not in our multiplex panel, but future studies will determine
if IL-33, IL-25, and TSLP are also dysregulated in IFN-β-KO mice during acute CHIKV infection.
Previous work in a mouse model of experimental autoimmune uveoretinitis (EAU) showed that in
vivo IFN-β treatment dampened IL-9 production by ex vivo stimulated splenocytes by an unknown
mechanism, suggesting that IFN-β may indirectly regulate ILC2 responses in multiple biological
contexts162. Altogether, our findings suggest a model in which IFN-β signals on synovial cells or
other nonhematopoietic cells in the foot tissue to modulate IL-9 induction, presumably by ILC2s,
during acute CHIKV infection. ILC2s have not been evaluated during CHIKV infection, but our
findings suggest that evaluating the contribution of ILC2s and IL-9 in acute CHIKV pathogenesis
may reveal important interactions between nonhematopoietic cells and innate immune responses.
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The current model of IFN-I-mediated protection during CHIKV infection is that IFN-I
signaling is absolutely required in nonhematopoietic cells to control and survive infection, yet how
these different cell types respond to IFN-I and CHIKV infection is poorly understood97,116. IFN-I
signaling is incredibly complex, and the functional outcome depends on many factors, including
concentration, IFN-I subtype affinity and half-life with the receptor, IFNAR surface levels, and
the cell type and biological context. Our studies add to the accumulating evidence that IFN-I
subtypes have distinct properties in vivo and that even the mechanisms underlying the differential
functions can vary depending on the biological context. Similar to other systems, we found that
the IFN-α’s are sufficient to control CHIKV replication and dissemination. In contrast, IFN-β
functioned to modulate the host immune response by a novel mechanism to protect against
neutrophil-mediated immunopathology during acute CHIKV infection. There are a number of
therapeutic agents approved for a variety of diseases that either target or augment the IFN-I
pathway. Our studies highlight that careful delineation of the biological activities of the IFN-I
subtypes may lead to more efficacious therapies with less off-target effects and also help explain
why the multigene nature of IFN-I is conserved across many species.

2.5 Materials and Methods
Mice
All animal experiments were performed in accordance and with approval of Washington
University Institutional Animal Care and Use Committee guidelines, and all mouse infection
studies were performed in an animal biosafety level 3 laboratory. All experiments were performed
with 4-week-old male mice. C57BL/6J (WT), interferon beta knockout (Ifnb-/-), and interferon
regulatory factor 7 knockout (Irf7-/-) mice were bred and maintained in our mouse colony before
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being transferred to the animal biosafety level 3 laboratory for CHIKV experiments. For some
experiments, 4-week-old Vav-Cre+/-Ifnar1fl/fl or Vav-Cre− Ifnar1fl/fl littermate controls were used,
which were also bred and maintained in our colony and genotyped prior to use in experiments.
Ifnb-/-, Irf7-/-, and Vav-Cre+Ifnar1fl/fl mice bred onto the C57BL/6J background were generously
provided by Michael S. Diamond (Washington University School of Medicine).
Virus experiments
A recombinant strain of CHIKV (LR2006 OPY1) was generously provided by S. Higgs
(Kansas State University) and generated from in vitro transcribed cDNA, as previously
described177. At 4 weeks of age, mice were inoculated in the left rear footpad with 103 PFU of the
LR2006 OPY1 strain of CHIKV in a volume of 10 μl. Infected mice were monitored daily for foot
swelling with digital calipers for 14-15 days. At the termination of experiments, mice were sedated
with a ketamine-xylazene cocktail and euthanized, and perfused via intracardiac injection with
PBS. Tissues (ipsilateral left ankle, contralateral right ankle, and ipsilateral quadriceps muscle)
were harvested into 0.65 mL PBS and then stored at −80°C until processing for viral burden.
“Ankle” refers to distal foot with the skin and digits removed, and “foot” refers to the distal foot
with cutaneous and subcutaneous tissues everted but still attached to the distal digits. For serum
analysis, blood was collected at the time of sacrifice and centrifuged for 10 min at 10,000g and
stored at −80°C.
Tissue viral burden
Organs were harvested into 0.65 ml of PBS and homogenized with 1.0 mm diameter
zirconia-silica beads with 2 pulses of 3,000 rpm for 30 seconds with a MagNA Lyser (Roche) prior
to plaque assay on BHK cells. 200 μL of serial dilutions of organ homogenates or serum in DMEM
with 1% FBS was added to BHK cells (5x105 cells for 6 well plates) and incubated for 1 hr at 37°C
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with rocking every 20 min. An MEM-agar overlay was then added to the cells and incubated for
approximately 60 hrs at 37°C or until plaques were visible by visual examination. Plates were then
fixed with 1% formaldehyde (30 min at room temperature), and agar plugs were removed. Plaques
were visualized using a 1% crystal violet solution and counted.
Histopathological analysis
The ipsilateral feet of infected mice were treated with Nair® to remove the fur, and then
the mice were sacrificed with a ketamine-xylazene cocktail and perfused by intracardiac injection
of PBS at the indicated day post infection. The infected whole foot tissue (with the skin intact) was
dissected above the ankle and fixed in 4% paraformaldehyde for 48 hours, followed by
decalcification in 10 mL of 14% acid-free EDTA (pH 7.2) for 10-14 days, with the buffer changed
every couple of days. Decalcified tissues were dehydrated with increasing ethanol gradients (30%,
50%, and then 70%) and subsequently embedded in paraffin with 5-um sections prepared. Tissue
sections were stained with hematoxylin and eosin (H&E). Embedding, sectioning, and staining
were performed by the Musculoskeletal Histology and Morphometry Core.
For quantification of cells into the joint space, H&E slides were imaged with a Zeiss Axio
Imager Z2 microscope equipped with a color CCD camera (Washington University Center for
Cellular Imaging). The investigator was not blinded to the identity of the samples at the time of
imaging, but all mid-foot synovial caps were imaged and then blinded for quantification by another
investigator. The data are represented as the number of cells per high-power field (HPF). For
overall inflammation scoring, the slides were blinded and scored by a pathologist. The pathologist
noted the absence or presence of joint space inflammation, myositis, and tenosynovitis and then
gave an overall inflammation score based on the following criteria: 0, no inflammation; 1, mild
inflammation; 2, moderate inflammation; 3, severe inflammation.
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Immune cell flow cytometry analysis
Mice were sacrificed 2 or 3 days after inoculation and perfused with PBS. The inoculated
foot was disarticulated at the ankle without fracturing the bone. Cutaneous and subcutaneous tissue
were everted but still attached to the distal foot and digits during digestion. Tissues were incubated
for 2 hours at 37°C in 5 mL digestion buffer with manual shaking every 20-30 min. Digestion
buffer consisted of RPMI (Sigma), type IV collagenase (2.5 mg/ml) (Sigma), DNase I (10 mg/ml)
(Sigma), 15 mM Hepes (Corning), and 10% FBS (BioWest). Digested tissues were passed through
a 70-um cell strainer and washed once with 40 mL PBS containing 4% FBS. The number of viable
cells was quantified by trypan blue staining.
The single cell suspension was transferred to a 96-well plate and incubated with antimouse CD16/CD32 (Clone 93; BioLegend) for 10 min at 4°C and then surface-stained in PBS
containing 4% FBS for 1 hour at 4°C with two separate panels of antibodies. All antibodies are
from BioLegend unless otherwise specified. Panel 1 consisted of anti-MHC-II PerCP-Cy5.5
(1:400, M5/114.15.2), anti-CD45 FITC (fluorescein isothiocyanate) (1:400, 30-F11), anti-CD11b
Brilliant Violet 605 (1:200, M1/70), anti-CD3e (1:200, 145-2C11) and anti-CD19 (1:400, 1D3,
BD Biosciences) Brilliant Violet 510 (dump gate), anti-CD11c Pacific Blue (1:200, N418), antiF4/80 APC-Cy7 (1:200, BM8), anti-Ly6C Alexa Fluor 700 (1:200, HK1.4), anti-MERTK PE
(phycoerythrin) (1:200, 2B10C42), anti-Ly6G PE-Cy7 (1:200, 1A8), and Fixable Viability Dye
eFluor 506 (1:500, eBioscience). Gating strategy for myeloid cells is illustrated in figure S2.1.
Panel 2 (data not shown) included anti-CD45 FITC (1:200, 30-F11), anti-CD11c Pacific
Blue (1:200, N418), anti-CD19 APC-Cy7 (1:400, 6D5), anti-CD8α Alexa Fluor 700 (1:200, 536.7), anti-CD3ε APC (1:200, 145-2C11), anti-CD4 PE-Cy7 (1:400, GK1.5), anti-NK1.1 PE
(1:200, PK136), and Fixable Viability Dye eFluor 506 (1:500, eBioscience). Cells were washed
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and fixed at 4°C for 10 min in 4% paraformaldehyde (Electron Microscopy Sciences). The fixed
cells were washed and resuspended in PBS containing 4% FBS. Cells were run on a LSR Fortessa
(Becton Dickinson) flow cytometer and analyzed using BD FACSDiva and FlowJo V10 software.
In vivo IFN blockade
BL6 mice were administered 1 mg of anti-mouse pan-IFN-α (TIF-3C5), 1 mg of antimouse IFN-β (HDb-4A7), or 1mg isotype control (PIP) (Leinco, St. Louis, MO) at 24h prior to
and again 24h post infection by an intraperitoneal route.
In vivo neutrophil depletion
BL6, IFN-β-KO, or IRF7-KO mice were treated with 0.25 mg of anti-mouse Ly6G (1A8)
or isotype control (Leinco, St. Louis, MO) at 1 day before and every other day through 7 days post
infection by intraperitoneal route. Neutrophil depletion was verified by whole blood staining at 6
or 8 dpi (data not shown).
Cytokine and chemokine analysis
Foot tissues (with the cutaneous and subcutaneous tissues everted but still attached to the
distal foot and digits) were harvested from euthanized infected mice at days 2 and 3 and collected
in 500 μL PBS with 0.1% BSA added and then homogenized using a MagNA Lyser (Roche).
Cytokine and chemokine levels in the homogenates were measured using Luminex technology
with a mouse 25-plex assay, as per the manufacturer’s instructions (Millipore).
Quantification and Statistical Analysis
All statistical analyses were performed with GraphPad Prism 7 software (San Diego, CA).
For foot swelling over time and viral burden analysis (3 experimental groups), two-way ANOVA
with Dunnet’s post-hoc multiple comparisons analysis was used. For cytokine/chemokine and
infiltrate analyses (2 experimental groups), two-way ANOVA with Sidak’s post-hoc multiple
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comparisons was used. For histological scoring and cells/HPF quantification one-way ANOVA
with Tukey’s post-hoc multiple comparisons test was used. All sample sizes were determined
based on our extensive experience with this model. P < 0.05 indicated statistically significant
differences.
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2.6 Figures

Figure 2.1 IFN-α and IFN-β both play protective roles in limiting clinical CHIKV disease
Mice were inoculated with 103 pfu of CHIKV (La Réunion) subcutaneously in the left rear foot pad. (A-B)
Foot swelling was measured daily for WT, IFN-β-KO, or IRF7-KO mice (A) or WT mice treated with 1
mg of anti-mouse IFN-α (TIF-3C5), 1 mg anti-mouse IFN-β (HDβ-4A7), or 1 mg isotype control antibody
at 24 hours prior to and post infection by intraperitoneal (IP) route (B). Data are reported as percent increase
in foot area (vertical x horizontal mm2) over baseline. Data are pooled from at least 2 independent
experiments with n = 18-22 mice per group (A) or n = 10 mice per group (B). All data are represented as
mean ± SEM, and if no error bar is present that indicates the error is smaller than the height of the symbol.
*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001 (2-way repeated measure ANOVA with Dunnett’s
post-hoc multiple comparisons analysis).
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Figure 2.2 IFN-β-KO, but not IRF7-KO, mice have increased cellular infiltration into the midfoot joint
spaces during acute CHIKV infection
Infected (103 pfu CHIKV) or mock-inoculated animals were sacrificed at 7 dpi, and histology of the
ipsilateral foot was performed. (A-B) Representative hematoxylin and eosin (H&E) staining of the
ipsilateral mid-foot joints in CHIKV-infected (A) or mock-inoculated mice (B) at 7 dpi (scale bar = 100
μm). (C) H & E slides were scored on a scale of 0 to 3 by a blinded pathologist for overall inflammation,
taking into consideration joint space inflammation, myositis, and synovitis for scoring. Criteria were: 0, no
inflammation; 1, mild inflammation; 2, moderate inflammation; 3, severe inflammation. (D) A blinded
investigator counted the number of inflammatory cells per high-power field (HPF) in the midfoot synovial
spaces. Data are depicted as the mean ± SEM. Histological results are at least two independent experiments
pooled with n = 4-6 per group. *, p<0.05; **, p<0.01; ***, p<0.001 (1-way ANOVA with Tukey’s posthoc multiple comparisons analysis).
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Figure 2.3 IFN-α, but not IFN-β, limits CHIKV replication and dissemination
Mice were inoculated with 103 pfu of CHIKV and then sacrificed and perfused with PBS at the indicated
time points. Infectious virus in the joints, muscle, and serum were determined by plaque assay in BHK cells
in (A) WT, IFN-β-KO mice, or IRF7-KO mice or (B) WT mice administered 1 mg anti-IFN-α, 1 mg antiIFN-β, or 1 mg isotype control by IP route at 24 h prior to and 24 h post infection. Dashed line represents
the limit of detection. Data are represented as median ± SEM. *, p<0.05; **, p<0.01; ***, p<0.001; ****,
p<0.0001 (2-way ANOVA followed by Dunnett’s post-hoc multiple comparisons test).
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Figure 2.4 IFN-α and IFN-β exert their protective effects during CHIKV arthritis by signaling on
nonhematopoietic cells
Vav-Cre+ IFNAR1flox/flox mice or Cre- IFANR1flox/flox littermate controls were infected with 103 pfu of
CHIKV (La Réunion). (A) Foot swelling was measured daily with digital calipers. Results are pooled from
2 independent experiments with n = 6-9 mice per group. Data are represented as the mean ± SEM. The
results were not statistically significant (p > 0.05) by 2-way repeated measure ANOVA with Dunnett’s
post-hoc multiple comparisons analysis. (B) Infectious virus in the joints, muscle, and serum were
determined by plaque assay at the indicated time points. Data are represented as median ± SEM.
*, p<0.05 (2-way ANOVA followed by Dunnett’s post-hoc multiple comparisons test).
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Figure 2.5 IFN-β deficient mice have increased neutrophil recruitment into the ipsilateral foot during
CHIKV infection
Mice were inoculated with 103 pfu of CHIKV via a subcutaneous route. The ipsilateral foot tissue was
collected at 2 and 3 dpi and digested with Collagenase IV (Sigma). The single cell suspension was surface
stained for immune cell markers and analyzed by flow cytometry. (A) Representative FACS plots showing
the percentages of CD11b+Ly6G+ neutrophils isolated from the feet of WT or IFN-β-KO mice at 2 dpi. B.
(B) Total number of isolated CD45+ leukocytes and total number or percentage of CD11b+Ly6G+
neutrophils, CD11b+Ly6C+Ly6G- monocytes, and F4/80+MERTK+ macrophages. Results are pooled from
2 independent experiments with n = 6-7 mice per group. Data represent the mean ± SEM. *, p<0.05; ****,
p<0.0001 (2-way ANOVA with Sidak’s post-hoc multiple comparisons test).
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Figure 2.6 Mice lacking IFN-β have increased early IL-9 levels in the ipsilateral foot
Mice were inoculated with 103 pfu of CHIKV via a subcutaneous route. Cytokine and chemokine levels on
day 2 and 3 in the ipsilateral foot was determined using Luminex technology (Millipore). Results are pooled
from two independent experiments with n = 6-7 mice per group. Data represent the mean ± SEM. Dashed
line represents limit of detection. *, p<0.05; ****, p<0.0001 (2-way ANOVA with Sidak’s post-hoc
multiple comparisons test).
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Figure 2.7 Depletion of neutrophils alleviates the increased foot swelling seen in CHIKV-infected IFNβ-KO mice, but not in IRF7-KO mice
WT, IFN-β-KO, or IRF7-KO mice were infected with 103 pfu of CHIKV. Mice were administered 0.25 mg
anti-Ly6G (1A8) or isotype control antibody by IP route beginning at 1 day before and continued every
other day through 7 dpi. Foot swelling was monitored daily and is reported as percent increase in foot area
(vertical x horizontal mm2) over baseline. Results are pooled from 2 independent experiments with n = 5-8
mice per group. Data are reported as the mean ± SEM. **, p<0.01; ***, p<0.001; **** p<0.0001 (2-way
repeated measure ANOVA with Dunnett’s post-hoc multiple comparisons analysis).

62

Figure S2.1 Gating strategy to identify myeloid cells recruited into the ipsilateral foot during CHIKV
infection
Mice were inoculated with 103 pfu of CHIKV via a subcutaneous route. The ipsilateral foot tissue was
collected at 2 and 3 dpi and digested with Collagenase IV (Sigma). The single cell suspension was surface
stained for immune cell markers and analyzed by flow cytometry. Gating strategy for WT and IFN-β-KO
mice at 2 dpi is shown. Gates were drawn based on an unstained sample.
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Chapter 3
Therapy with CTLA4-Ig and an antiviral monoclonal
antibody controls chikungunya virus arthritis

This chapter contains data published in the following publication with significant contribution
from Jonathan Miner.
J. J. Miner*, L. E. Cook*, J. P. Hong, A. M. Smith, J. M. Richner, R. M. Shimak, A. R. Young,
K. Monte, S. Poddar, J. E. Crowe Jr., D. J. Lenschow, M. S. Diamond, Therapy with CTLA4-Ig
and an antiviral monoclonal antibody controls chikungunya virus arthritis. Sci. Transl. Med. 9,
eaah3438 (2017).
*co-first authors
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3.1 Abstract
In 2013, chikungunya virus (CHIKV) transmission was documented in the Western
Hemisphere, and the virus has since spread throughout the Americas with more than 1.8 million
people infected in more than 40 countries. CHIKV targets the joints, resulting in symmetric
polyarthritis that clinically mimics rheumatoid arthritis and can endure for months to years. At
present, no approved treatment is effective in preventing or controlling CHIKV infection or
disease. We treated mice with eight different disease-modifying antirheumatic drugs and identified
CLTA4-Ig (abatacept) and tofacitinib as candidate therapies based on their ability to decrease acute
joint swelling. CTLA4-Ig reduced T cell accumulation in the joints of infected animals without
affecting viral infection. Whereas monotherapy with CTLA4-Ig or a neutralizing anti-CHIKV
human monoclonal antibody provided partial clinical improvement, therapy with both abolished
swelling and markedly reduced levels of chemokines, proinflammatory cytokines, and infiltrating
leukocytes. Thus, combination CTLA4-Ig and antiviral antibody therapy controls acute CHIKV
infection and arthritis and may be a candidate for testing in humans.

3.2 Introduction
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes severe acute
and chronic polyarthritis. CHIKV was first isolated in Tanzania in 1947, but the virus has emerged
rapidly over the last decade, causing outbreaks in the islands of the Indian Ocean, in Southern
Europe, and in Southeast Asia178,179. In 2013, CHIKV spread to the Western Hemisphere and, by
the end of 2015, had infected more than 1.8 million people in North America, Central America,
and South America. The acute symptoms of CHIKV infection include fever and rash, which
typically resolve within a few days, and joint and muscle pain23. CHIKV and other arthritogenic
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alphaviruses directly invade the synovium to cause inflammatory arthritis, which is characterized
by articular swelling and prolonged morning stiffness23,52. CHIKV-induced arthritis in humans can
persist, with as many as 60% of individuals progressing to chronic disease that lasts from months
to years20,23,180,181. Epidemiological projections suggest that there are currently about 400,000
individuals in the Western Hemisphere with chronic CHIKV arthritis22.
Chronic CHIKV arthritis clinically is similar to seronegative rheumatoid arthritis (RA), an
autoimmune disease characterized by symmetrical joint pain, swelling, and morning stiffness23,182–
184

. Treatment with newer disease-modifying antirheumatic drugs (DMARDs) has been effective

in preventing the bone erosions and deformities seen in patients with untreated RA. Whether
chronic CHIKV arthritis causes erosive disease remains controversial, although there are reports
of bone erosions in patients infected with CHIKV182. Effective treatment of RA relies on early
diagnosis, because erosions can occur within months of onset of the disease185. Because CHIKV
and RA exhibit significant clinical overlap, there is potential for confusing the diagnoses and
inadvertently treating CHIKV arthritis with DMARD therapy23.
Over the last 20 years, studies in patients with RA have demonstrated that oral and
biological DMARDs prevent joint pain, swelling, and damage. Oral DMARDs include
hydroxychloroquine, methotrexate, and sulfasalazine, whereas biological DMARDs include the
anticytokine antibodies and Ig chimeras [for example, anti–tumor necrosis factor–α (TNF-α) and
anti–interleukin-6 (IL-6) receptor]. Other biological DMARDs block T cell costimulation
(CTLA4-Ig) or deplete B cells (anti-CD20). Among the newest drugs used to treat RA is
tofacitinib, an oral DMARD that inhibits JAK (Janus kinase)/STAT (signal transducers and
activators of transcription) signaling and broadly blunts cytokine responses186,187. However, many
DMARDs, by virtue of their immunosuppressive properties, may predispose to serious microbial
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infections. Thus, there is a need to determine whether DMARDs are effective, benign, or
deleterious in the treatment of CHIKV arthritis. The current standard of care for CHIKV arthritis
is treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), although these often do not
ameliorate symptoms23,26. One trial compared chloroquine (a DMARD) to meloxicam (an NSAID)
and found no difference in efficacy, although a placebo group was not included in the trial design26.
Another open-label study examined a combination of hydroxychloroquine and methotrexate in the
treatment of CHIKV arthritis and found that some patients partially responded to therapy, although
~50% of patients did not achieve significant improvement in disease score188.
Subcutaneous inoculation of young wild-type (WT) immunocompetent C57BL/6 mice
with pathogenic strains of CHIKV results in acute foot swelling, myositis, and arthritis51,52. In this
model, swelling resolves within the first 2 weeks of infection, although mild chronic disease can
be observed histologically for weeks to months51,52,189. This finding contrasts with the disease in
humans, which are natural hosts and frequently have a protracted clinical disease course. Human
patients with CHIKV arthritis have increased numbers of circulating, activated cytolytic CD8 + T
cells, as do patients with untreated RA23. Gene expression signatures observed in mouse models
of CHIKV arthritis and RA suggested overlapping contributions of T cell–associated pathways in
these diseases190. Mice lacking or depleted of CD4+ T cells have reduced foot swelling and arthritis
during acute CHIKV infection, suggesting that CD4+ T cells contribute to the pathology of
arthritis79. Inflammatory monocytes also are thought to play an initiating role in CHIKV arthritis
in mice, because inhibiting production of monocyte chemoattractant protein-1 (MCP-1) with
bindarit improved the disease191. Finally, treatment of mice with anti-CHIKV monoclonal
antibodies (mAbs) 1 day before infection prevents arthritis, but whether therapy after infection is
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effective has not been studied29,192,193. Moreover, no previous study has tested the efficacy of
clinically available DMARDs against CHIKV arthritis in mice.
Here, we examined the efficacy of several U.S. Food and Drug Administration (FDA)–
approved RA therapies in a mouse model of CHIKV infection. We identified two DMARDs
(CTLA4-Ig and tofacitinib) with efficacy during acute CHIKV arthritis. In particular, CTLA4-Ig,
when paired with the neutralizing anti-CHIKV human mAb 4N12, was highly effective at reducing
joint inflammation, periarticular swelling, migration of inflammatory leukocytes, and infection
even when administered several days after virus inoculation. Thus, combination of antiinflammatory and antibody-based antiviral therapy may serve as a model for treating humans with
arthritis caused by CHIKV or other related viruses.

3.3 Results
Screen of candidate oral and biological DMARDs for treatment of acute CHIKV
arthritis in mice. On the basis of previous data showing that immune cells and proinflammatory
cytokines contribute to CHIKV arthritis in mice and our study showing that CHIKV arthritis
clinically can mimic seronegative RA, we hypothesized that some of the existing FDA-approved
therapies for RA might ameliorate acute CHIKV arthritis23,79. To test this idea, we performed a
multiarm prospective study (Fig. 3.1A) by inoculating 224 4-week-old WT mice subcutaneously
in the left rear foot with 103 focus-forming units (FFU) of a pathogenic clinical isolate of CHIKV
(La Reunion, 2006). Mice were divided into groups of 28 animals that received one of the
following treatments beginning on day 3 after infection: methylprednisolone, naproxen,
methotrexate, etanercept (soluble human TNF-α receptor), CTLA4-Ig (abatacept), oral gavage
vehicle control, or tofacitinib (JAK inhibitor). All of the biological agents that we used have been
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shown previously to have activity in mice186,194,195. We chose day 3 after infection to initiate
treatment, because this represents the time point of the first peak of clinically apparent foot
swelling in the WT C57BL/6 mouse model of CHIKV infection (Fig. 3.1B). Animals were
followed for clinical joint swelling in the ipsilateral foot and viral yield at different times after
infection and treatment.
Treatment with CTLA4-Ig or tofacitinib at day 3 ameliorated foot swelling on day 7 after
infection at the point of peak clinical disease [Fig. 3.1, C to F; 9.0 mm2 (injection control) versus
7.8 mm2 (CTLA4-Ig), P < 0.005 and 9.3 mm2 (oral control) versus 8.5 mm2 (tofacitinib), P <
0.005]. Other treatments had no significant effect at the dose tested in our experiments. To assess
the systemic and local impact on viral burden of DMARD treatment, we evaluated CHIKV RNA
levels on day 7 in serum and joint tissues. Remarkably, none of the therapies affected viral RNA
levels in the right ankle or left ankle at day 7 or day 28 after infection compared to controls (Fig.
3.1, G to J; P > 0.1). Thus, CTLA4-Ig and tofacitinib ameliorate joint and periarticular
inflammation in mice during the acute phase without substantively altering the viral burden in
inflamed tissues. The beneficial effect of CTLA4-Ig, which blocks T cell activation, is consistent
with data suggesting that CD4+ T cells contribute to immunopathology associated with CHIKV
arthritis79,194.
Combination therapy with CTLA4-Ig and an anti-CHIKV human mAb ameliorates
acute CHIKV arthritis in mice. We next tested whether combination immunomodulatory and
antiviral therapy might have greater beneficial effects. Potently neutralizing human anti-CHIKV
mAbs previously were shown to protect against CHIKV-induced lethality in immunocompromised
Ifnar1−/− mice, even when administered at late time points after infection28. We administered either
a single 600-μg dose of a control immunoglobulin G (IgG), 300 μg of CTLA4-Ig, 300 μg of anti69

CHIKV mAb (4N12, a neutralizing anti-CHIKV human mAb), or 300 μg each of CTLA4-Ig +
anti-CHIKV mAb (Fig. 3.2A) 3 days after CHIKV infection. Whereas either anti-CHIKV mAb or
CTLA4-Ig partially reduced foot swelling at day 7, the combination completely abolished it (10.8
mm2 versus 6.6 mm2, P < 0.0001) relative to untreated or control IgG–treated animals (Fig. 3.2, A
and B). Thus, anti-CHIKV mAb therapy initiated after disease onset can partially treat the acute
clinical arthritis associated with CHIKV infection, and combination therapy with anti-CHIKV
mAb and the immunomodulator CTLA4-Ig completely resolves clinical disease in mice within a
few days of treatment.
Viral burden in CHIKV-infected mice treated with CTLA4-Ig and anti-CHIKV mAb.
To confirm the activity of the anti-CHIKV mAb in this model, we assessed its effects on viral
burden. Treatment with anti-CHIKV mAb (alone or in combination with CTLA4-Ig) at day 3
eliminated infectious virus in the joints of infected mice within 2 days, as we observed a ~10,000fold reduction in the ipsilateral ankle (Fig. 3.3A; P < 0.0005) and a ~100-fold reduction in the
contralateral ankle (Fig. 3.3A; P < 0.05). Viral burden in mice treated with only CTLA4-Ig was
not reduced in either the ipsilateral or contralateral ankle (Fig. 3.3A). Although infectious CHIKV
cannot be detected after day 7 in this mouse model (or during the chronic phase in humans),
CHIKV RNA persists in joint tissues for months23,52,54. Because persistent viral RNA is a
pathogen-associated molecular pattern and may contribute to CHIKV arthritis, we tested whether
anti-CHIKV mAb treatment would reduce viral RNA levels23,54. Although we did not observe a
reduction in viral RNA levels in the ipsilateral foot joints (P > 0.1), other extremity joints exhibited
a ~10-fold reduction in viral RNA on day 7 after infection, including the contralateral ankle and
ipsilateral wrist (Fig. 3.3B; right ankle, P < 0.005; left wrist, P < 0.05). On day 28, there was a
trend toward reduced RNA in distal joint tissues of animals treated with anti-CHIKV mAb,
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although this did not attain statistical significance (Fig. 3.3C; P = 0.2). Collectively, these results
show that treatment with an anti-CHIKV mAb (alone or in combination with CTLA4-Ig) rapidly
eliminates infectious virus within 2 days and reduces but fails to clear viral RNA in affected
tissues.
Cytokine and chemokine analysis in CHIKV-infected mice treated with CTLA4-Ig
and anti-CHIKV mAb. To begin to define the basis for reduced joint swelling associated with
treatment, we analyzed the effects on local cytokine and chemokine production. Using a
multiplexed assay, we measured cytokine and chemokine levels in the ipsilateral foot on day 7
after infection in animals that received either control mAb, CTLA4-Ig, anti-CHIKV mAb, or
combination therapy with CTLA4-Ig and anti-CHIKV mAb. Monotherapy with CTLA4-Ig
reduced levels of CXCL10 and macrophage inflammatory protein-1β (MIP-1β) (Fig. 3.4, A and
B; P < 0.05), whereas treatment with anti-CHIKV mAb reduced levels of MCP-1 (Fig. 3.4C; P <
0.05). In comparison, combination therapy had more profound anti-inflammatory effects and
resulted in decreased levels of many of the measured chemokines (for example, KC, CXCL10,
MCP-1, MIP-1β, and RANTES; Fig. 3.4, A to I; P < 0.05) in the joint tissue.
Histological and immune infiltrate analysis of the ipsilateral midfoot joints in
CHIKV-infected mice treated with CTLA4-Ig and anti-CHIKV mAb. Histological analysis of
joint tissues in the ipsilateral foot revealed reduced leukocyte infiltration into the midfoot joints of
mice receiving CTLA4-Ig and combination therapy with CTLA4-Ig and anti-CHIKV mAb (Fig.
3.5, A to F; yellow arrows, moderate to severe synovitis; white arrows, absent or mild synovitis).
We next quantitated the number of inflammatory cells per high-power field (HPF) in the synovial
space of the midfoot. CTLA4-Ig and combination therapy with CTLA4-Ig and anti-CHIKV mAb
resulted in decreased inflammatory cell infiltration into the synovial space (52 cells per HPF in the
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control group, 22 cells per HPF in CTLA4-Ig group, and 9 cells per HPF in the CTLA4-Ig + antiCHIKV mAb group, P < 0.05 and P < 0.0001, respectively). Histological analysis did not reveal
evidence of bone erosion, proteoglycan loss, or effects on expression of receptor activator of
nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) (fig. S3.1). Consistent with a
role for CTLA4-Ig in modulating immune cell recruitment, administration of CTLA4-Ig 1 day
before infection resulted in reduced swelling on day 7 but not on day 3 (fig. S3.2), a time point at
which subcutaneous edema but not immune cell infiltration is observed. To quantitate differences
in immune cell infiltration into the entire foot at day 7 after infection, we analyzed by flow
cytometry how CTLA4-Ig and anti-CHIKV mAb treatments affected the total numbers of immune
cells in the soft tissues of the ipsilateral foot, which included the skin, muscle, and joints. After
treatment with CTLA4-Ig or a combination of CTLA4-Ig and anti-CHIKV mAb, we observed
about a three- to fourfold reduction in the number of total CD45+ leukocytes (Fig. 3.6, A and B; P
< 0.0005) with markedly reduced numbers of Ly6C+CD11b+ inflammatory monocytes, natural
killer cells, and CD8+ T cells, and a nearly complete absence of CD4+ T cells (Fig. 3.6, B to G).
By contrast, treatment with the anti-CHIKV mAb alone did not reduce the number of infiltrating
CD45+ cells or individual leukocyte subsets into the infected foot (Fig. 3.6, A to G).
Clinical assessment of the response to CTLA4-Ig treatment in CHIKV-infected WT
and TCRβδ−/− mice. CTLA4-Ig blocks T cell costimulation, but it can also have
immunomodulatory effects on antigen-presenting cells (APCs)194,196. Human CTLA4-Ig, which
was used in our studies, binds murine B7.1 and B7.2 antigens and can modulate APC
function197,198. We assessed APC activation on day 7 after infection but saw no difference in CD80,
CD86, and class II major histocompatibility complex marker expression in APCs isolated from the
spleen and feet of control and CTLA4-Ig–treated mice (fig. S3.3). To test whether CTLA4-Ig
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exerted its therapeutic benefits via T cells, we compared the response to CTLA4-Ig and a control
mAb in CHIKV-infected WT and TCRβδ−/− mice, the latter of which lack both αβ and γδ T cells.
As we observed a beneficial effect of CTLA4-Ig in WT animals (Fig. 3.7, A and C; P < 0.005) but
not in TCRβδ−/− mice (Fig. 3.7, B and C; P > 0.9), CTLA4-Ig reduces swelling during acute
CHIKV infection in part via its action on T cells.

3.4 Discussion
The worldwide emergence of CHIKV has created a need to identify treatments, as
epidemiological estimates suggest there are millions suffering from acute arthritis and at least
~400,000 people in the Western Hemisphere suffering from chronic CHIKV arthritis22,180. We
reasoned that established therapies used to treat other forms of inflammatory arthritis (for example,
rheumatoid or psoriatic arthritis) also might mitigate CHIKV arthritis. Our experiments identified
CTLA4-Ig and tofacitinib as candidate DMARD therapies based on efficacy against acute CHIKV
arthritis in mice.
Immunopathology likely contributes to the pathogenesis of CHIKV arthritis. Previous
studies using Rag2−/− animals suggested that the response depends on B and T cells, because
Rag2−/− animals had no ipsilateral foot swelling79. Leukocyte subsets infiltrating the peripheral
joints of CHIKV-infected mice primarily consist of T cells, inflammatory monocytes, and
macrophages52. When we blocked T cell costimulation with CTLA4-Ig, we observed reduced
infiltration of T cells and inflammatory monocytes into the joints of infected animals, although
this was not sufficient to eliminate the clinical disease completely. Treatment of TCRβδ−/− mice
with CTLA4-Ig had no effect on joint swelling, suggesting that CTLA4-Ig ameliorates clinical
disease primarily via its action on T cells. These findings are consistent with previous studies
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suggesting that joint swelling in the foot of CD4−/− animals is reduced in severity but not
completely controlled79. Our findings suggest that other inhibitors of CD4+ T cell function also
might limit musculoskeletal disease associated with CHIKV infection. Teo et al. recently
demonstrated that treatment with fingolimod, an agonist of the sphingosine 1-phosphate receptor,
limited infiltration of CD4+ T cells into CHIKV-infected joints and adjacent muscle in mice,
resulting in reduced joint swelling and muscle necrosis199.
Previous studies showed that mouse and human antiviral antibodies could prevent CHIKV
arthritis in mice when administered before infection or protect against lethality in highly
immunocompromised Ifnar1−/− mice28,54,192. We found that treatment of WT mice 3 days after
CHIKV infection with an antiviral human mAb reduced but did not eliminate joint swelling,
although infectious virus could not be detected in the joints within 2 days of therapy. Foot swelling
likely depends on multiple factors including synovitis, myositis, and edema resulting from
production of proinflammatory cytokines52. The anti-CHIKV mAb eliminated infectious virus
within 2 days of its administration and reduced foot swelling without altering leukocyte infiltration
into joints of infected animals, suggesting that leukocyte recruitment is not the only factor that
affects disease severity in this model. Local cytokine production in specific compartments (for
example, serum, muscles, or joints) independently may affect the virus-induced swelling or edema.
Future histological studies may define better the precise mechanism by which neutralization of
infectious CHIKV by antiviral antibodies ameliorates foot swelling.
The type I interferon (IFN-I) response is important in controlling CHIKV infection.
Ifnar1−/− mice lacking type I IFN signaling are highly vulnerable to disseminated infection with
CHIKV and succumb within days due to high levels of virus in the brain and spinal cord56.
Remarkably, treatment with tofacitinib, which blocks JAK/STAT signaling that is downstream of
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IFNAR1 and other cytokine receptors, reduced clinical disease without ostensible effects on
morbidity or mortality. This result may be related to the pharmacodynamics of tofacitinib
including its short half-life186. Tofacitinib therapy may blunt cytokine production and/or leukocyte
infiltration without enhancement of CHIKV replication. Nevertheless, because tofacitinib is
known to enhance the risk of some viral infections, including varicella zoster virus, future
combination therapy studies with tofacitinib and an antiviral mAb may be warranted200.
Anecdotal reports in humans have suggested that methotrexate may be effective for
treatment of CHIKV arthritis188,201. In our studies, a low dose of methotrexate did not provide
benefit against acute arthritis. It remains possible that methotrexate would show greater benefit if
higher doses were used. Mouse models of Ross River virus arthritis previously revealed
exacerbation of disease after treatment with etanercept, whereas an uncontrolled study in humans
suggested that blockade of TNF-α provided some benefit in 13 patients who were diagnosed with
a “chronic rheumatologic disease” after acute CHIKV infection201,202. However, it is important to
note that some patients infected with CHIKV may develop rheumatologic disease sporadically or
coincidentally after CHIKV infection. In a controlled study of mice infected with CHIKV, we did
not find a benefit of etanercept therapy with acute CHIKV arthritis, but we were unable to assess
chronic disease because of the histopathological absence of frank arthritis during the chronic
phase. In light of our animal model results and the anecdotal nature of previous human studies, it
seems that rigorous, blinded, placebo-controlled studies in human patients are necessary to define
which DMARD therapies may be safe and optimal in patients with chronic CHIKV arthritis.
CHIKV and related arthritogenic alphaviruses directly invade the joints and leave
persistent viral RNA in the joints and surrounding tissues even in the absence of detectable
infectious virus54. In previous studies, we found that most CHIKV-infected control C57BL/6 mice
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did not exhibit histopathological evidence of chronic arthritis 1 month after infection, although
there was mild chronic tenosynovitis and myositis in some animals52. Because we could readily
detect viral RNA in the joints at day 28, our studies suggest that persistent viral RNA may not be
sufficient to cause clinically apparent chronic arthritis in mice and that other factors must
contribute to pathogenesis. Thus, it remains to be determined whether our combination treatment
with an antiviral antibody and CTLA4-Ig has beneficial effects in chronic CHIKV arthritis. Other
animal models with more severe chronic disease (for example, nonhuman primates) may be
required to address these questions.
The beneficial effects of CTLA4-Ig and antiviral antibody therapy on CHIKV arthritis
must be interpreted with caution because there are limitations with the mouse model. Unlike
humans, mice are not natural hosts for CHIKV and therefore do not develop the severe, debilitating
arthritis that is commonly observed in humans. Because CHIKV causes less severe disease in mice,
it remains possible that immunomodulatory therapies, including CTLA4-Ig, may have no or even
deleterious effects in humans.
The concept of combination antiviral and immunomodulatory therapy is a unique approach
for the treatment of infectious diseases. The near-complete effectiveness of combination therapy
in our mouse model of acute CHIKV arthritis has implications for treatment of other viral
infections in which both virus- and immune-mediated pathology result in morbidity and mortality
(for example, influenza and severe acute respiratory syndrome coronavirus). Given the large
number of clinically available biological and small molecular DMARDs, this work may provide
greater impetus for studies that test combination antiviral and immunomodulatory therapies for the
treatment of infectious diseases.
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3.5 Materials and Methods
Study design
We initiated this study to determine whether anti-inflammatory and antiviral therapy
control acute CHIKV arthritis in mice. Our initial observation was that treatment with antiviral
antibody reduced infectious viral burden in the ipsilateral joint and that therapy with CTLA4-Ig
diminished recruitment of T cells and inflammatory monocytes as well as the accumulation of
proinflammatory cytokines. Subsequent histological analysis confirmed these findings. We
measured viral titers and RNA in tissues, immunologic parameters (including influx of specific
cell subtypes into the joints and surrounding tissues), and cytokine levels. Sample sizes and end
points were selected on the basis of our extensive experience with these systems. Mice were ageand sex-matched between groups. Histological analysis was performed in a blinded fashion. Initial
footpad measurements were performed by three individuals in an unblinded fashion. However, the
measurements after CTLA4-Ig treatment were reproduced by a fourth individual who performed
a blinded assessment. Investigators were not blinded when conducting virus tissue burden analysis,
cytokine measurements, or flow cytometry analysis.
Mouse experiments
All animal experiments were performed in accordance and with approval of Washington
University Institutional Animal Care and Use Committee guidelines, and all mouse infection
studies were performed in an animal biosafety level 3 laboratory. All experiments were performed
with 4-week-old C57BL/6 mice or with TCRβδ−/− mice that were obtained commercially (The
Jackson Laboratories).
Virus infection studies
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A recombinant LR2006 OPY1 strain of CHIKV was provided by S. Higgs (Kansas State
University) and generated from in vitro transcribed cDNA, as previously described177. At 4 weeks
of age, mice were inoculated in the left rear footpad with 103 FFU of the LR2006 OPY1 strain of
CHIKV in a volume of 10 μl. Infected mice were monitored daily for foot swelling with digital
calipers for 28 days. At the termination of experiments, mice were sedated with a ketaminexylazene cocktail and euthanized, and perfused via intracardiac injection with PBS. Tissues
(injected left ankle, contralateral ankle, and ipsilateral wrist) were harvested and snap-frozen on
dry ice and stored at −80°C until processing for RNA isolation. For serum analysis, blood was
collected at the time of sacrifice and centrifuged for 10 min at 10,000g and stored at −80°C. In
some experiments, serum and joint tissues were isolated from mice on day 5 after infection for
subsequent analysis by focus-forming assay.
Tissue viral burden analysis
Focus-forming assays were performed as previously described192. Briefly, tissue
homogenates or serum were incubated for 90 min on a monolayer of Vero cells in 96-well plates,
and then cells were overlaid with 1% (w/v) methylcellulose in modified Eagle media supplemented
with 4% fetal bovine serum (FBS). Plates were harvested 18 to 24 hours later and fixed with 1%
paraformaldehyde (PFA) in PBS. The plates were incubated sequentially with chimeric CHK-9
(500 ng/ml)192 and horseradish peroxidase–conjugated goat anti-human IgG in PBS supplemented
with 0.1% saponin and 0.1% bovine serum albumin. CHIKV-infected foci were visualized using
TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot 5.0.37 macroanalyzer
(Cellular Technologies Ltd).
Real-time qRT-PCR analysis
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RNA was extracted from tissue using the RNeasy Mini Kit (Qiagen). The quantity of
CHIKV RNA was determined by qRT-PCR using the TaqMan RNA-to-CT 1-Step Kit (Applied
Biosystems) with an E1-specific primer/probe set203. Two microliters of the isolated RNA was
analyzed by qRT-PCR and compared to a standard curve generated from RNA isolated from a
CHIKV stock to determine FFU equivalents.
Therapeutic agents
4N12 is a human IgG1 mAb that neutralizes CHIKV infection and has been described
previously28. Antibody was purified from hybridoma supernatants by protein G affinity
chromatography. Methotrexate, CTLA4-Ig (abatacept), and etanercept were obtained from the
Center for Advanced Medicine Rheumatology Clinic (St. Louis, MO). Naproxen sodium and
methylprednisolone acetate were purchased from Sigma. The isotype control antibody [humanized
anti–West Nile virus antibody (E16)] was produced in Chinese hamster ovary cells and purified
by protein G affinity chromatography204.
Histopathological analysis
Infected mice were sacrificed and perfused by intracardiac injection of 4% PFA at the
indicated days after infection. The infected ankle/foot tissue was dissected and fixed in 4%
PFA/PBS for 48 hours, followed by decalcification in 14% acid-free EDTA for 10 to 14 days.
Decalcified tissues were embedded in paraffin, and 5-μm sections were stained with hematoxylin
and eosin (H&E) and evaluated by light microscopy. Embedding, sectioning, and staining were
performed by the Musculoskeletal Histology and Morphometry Core at Washington University
School of Medicine. All samples were visualized using a Nikon Eclipse microscope equipped with
a QICAM 12-bit camera (QImaging) and processed with QCapture software using the same
exposure times.
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Cytokine/chemokine analysis
Ankles were harvested from euthanized infected mice at day 7 and collected in 500-μl PBS
and homogenized using a MagNA Lyser (Roche). Cytokine levels were measured using Luminex
technology with a Bio-Plex Pro mouse cytokine 13-plex assay (Millipore).
Immune cell analysis
Mice were sacrificed 7 days after inoculation and perfused with PBS. The inoculated foot
was disarticulated at the ankle without fracturing the bone. Cutaneous and subcutaneous tissue
were everted but still attached to the distal foot and digits during digestion. Tissues were incubated
for 2 hours at 37°C in digestion buffer [RPMI, type I collagenase (2.5 mg/ml) (Sigma), DNase I
(10 mg/ml) (Sigma), 15 mM Hepes, 10% FBS]. Digested tissues were passed through a 70-μm cell
strainer. The number of viable cells was quantified by trypan blue staining. Isolated cells were
incubated with anti-mouse CD16/CD32 (Clone 93; BioLegend) for 10 min at 4°C and then surfacestained in PBS containing 5% FBS for 30 min at 4°C with the following antibodies: anti–CD3eFITC (fluorescein isothiocyanate) (eBioscience), anti–CD4-PE (phycoerythrin) (BD Biosciences),
anti–CD8a-PerCP/Cy5.5 (BioLegend), anti–NK1.1-PE/Cy7 (BioLegend), anti–CD45-Brilliant
Violet 605 (BioLegend), anti–Ly6C-Brilliant Violet 421 (BD Biosciences), anti–Ly6G–Alexa
Fluor 700 (BioLegend), and anti–CD19-APC/Cy7 (BioLegend). Cells were washed and incubated
at room temperature for 30 min in Foxp3 Fixation/Permeabilization buffer (eBioscience). The
fixed cells were washed with Permeabilization buffer (eBioscience) and stained in
Permeabilization buffer overnight at 4°C with anti–Foxp3–Alexa Fluor 647 (BioLegend). Cells
were run on a LSR II (Becton Dickinson) flow cytometer and analyzed using BD FACSDiva and
FlowJo software.
Statistical analysis
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All data were analyzed with GraphPad Prism software. For viral burden analysis, cytokine
measurements, and numbers of infiltrating leukocytes, data were analyzed by the Mann-Whitney
test, ANOVA, or Kruskal-Wallis test with a Dunn’s post hoc analysis. P < 0.05 indicated
statistically significant differences.
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3.6 Figures

Figure 3.1 Screen of candidate oral and biological DMARDs for treatment of acute CHIKV arthritis in
mice
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. (A) Schematic depicting the two
controls and six treatment arms. Medications and doses were methylprednisolone (0.5 mg/kg, IP) daily
from 3-7 dpi, naproxen (10 mg/kg, IP) daily from 3-7 dpi, methotrexate (0.3 mg/kg, IP) once weekly (2
doses: 3, 10 dpi), etanercept (300 μg, IP) 1 dose on day 3, CTLA4-Ig (300 μg, IP) 1 dose on day 3, and
tofacitinib (50 mg/kg) oral gavage daily from 3-7 dpi. For subsequent studies of CTLA4-Ig, an isotype
control antibody was used. (B) Experimental design included treatment at 3 dpi and harvests on 7 and 28
dpi for the indicated analyses. Throughout the time course, foot swelling was measured using digital
calipers. (C) Foot swelling (area in mm2) on day 7 compared to day 0 for all injected therapies. (D) Foot
swelling over time for injection control and CTLA4-Ig–treated animals. (E) Foot swelling on day 7
compared to day 0 for tofacitinib and oral vehicle control. (F) Foot swelling over time for oral vehicle
control and tofacitinib-treated animals. (G to J) qRT-PCR analysis of viral RNA levels in the left and right
ankles at 7 and 28 dpi for all treatment groups. Results in (C) to (J) are from at least two independent
experiments with n = 28 per treatment group for measurement data from days 0 to 7 and n= 7-8 for viral
burden analysis on days 7 and 28. Data represent the means (C to F) or median (G to J) ± SEM. *P < 0.05,
**P < 0.005, ****P < 0.0001 [two-way ANOVA for analysis of swelling curves, Mann-Whitney for day 7
tofacitinib analysis, and Kruskal-Wallis with Dunn’s post hoc analysis for day 7 injected medication and
viral burden analysis].

82

Figure 3.2 Combination therapy with CTLA4-Ig and an anti-CHIKV human mAb ameliorates acute
CHIKV arthritis in mice
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. (A) Foot swelling (area in mm2)
from day 0 through day 15 in mice receiving at day 3 a single IP injection of 600 μg of isotype control
antibody, 300 μg of CTLA4-Ig, 300 μg of anti-CHIKV mAb (4N12), or a combination of 300 μg of CTLA4Ig and 300 μg of anti-CHIKV mAb. Data are pooled from two independent experiments (n = 15 to 19
animals per group). (B) Representative photographs of ipsilateral foot swelling in the control mAb or
combination therapy (CTLA4-Ig + anti-CHIKV mAb) groups. Data represent the means ± SEM. **P <
0.005, ****P < 0.0001 (two-way ANOVA with multiple comparisons).
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Figure 3.3 Viral burden in CHIKV-infected mice treated with CTLA4-Ig and anti-CHIKV mAb
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. Mice received at day 3 a single
IP injection of 600 μg of isotype control antibody, 300 μg of CTLA4-Ig, 300 μg of anti-CHIKV mAb, or a
combination of 300 μg of CTLA4-Ig and 300 μg of anti-CHIKV mAb. (A) Infectious virus in joints and
serum quantitated by focus-forming assay on day 5 after infection. (B and C) Real-time qRT-PCR analysis
of viral RNA levels in the ipsilateral (left) and contralateral (right) ankles and left wrist at days 7 and 28
after infection. Results are pooled from two independent experiments with n = 10 per treatment group for
viral RNA data and n = 8 for focus-forming assay data. Data represent the median ± SEM. *P < 0.05, **P <
0.005, ***P < 0.0005 (Kruskal-Wallis with Dunn’s post hoc analysis).
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Figure 3.4 Cytokine and chemokine analysis in CHIKV-infected mice treated with CTLA4-Ig and antiCHIKV mAb
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. Mice received at day 3 a single
IP injection of 600 μg of isotype control antibody, 300 μg of CTLA4-Ig, 300 μg of anti-CHIKV mAb, or a
combination of 300 μg of CTLA4-Ig and 300 μg of anti-CHIKV mAb. (A to I) Cytokine and chemokine
levels on day 7 in the ipsilateral foot of mice in each treatment group. Analytes included CXCL10 (A),
MIP-1β (B), MCP-1 (C), KC (D), RANTES (E), CXCL9 (F), MIP2 (G), IL-1β (H), and TNF-α (I). Results
are pooled from two independent experiments with n = 8 mice per treatment group. Data represent the
means ± SEM. *P < 0.05, **P < 0.005 (Kruskal-Wallis with Dunn’s post hoc analysis).
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Figure 3.5 Representative H&E staining of the ipsilateral midfoot joints in CHIKV-infected mice
treated with CTLA4-Ig and anti-CHIKV mAb
(A to F) Mice were inoculated with either PBS (A; mock) or 103FFU of CHIKV (B to F) via a subcutaneous
route. Animals were sacrificed, and histology of the ipsilateral foot was performed on day 7 after infection.
CHIKV-infected mice received at day 3 a single intraperitoneal injection of 600 μg of isotype control
antibody (B), 300 μg of anti-CHIKV mAb (C), 300 μg of CTLA4-Ig (D), or a combination of 300 μg of
CTLA4-Ig and 300 μg of anti-CHIKV mAb (E). The number of inflammatory cells per HPF in the midfoot
synovial space was quantitated in a blinded fashion (F). Results are representative of at least two
independent experiments with n = 4 per treatment group and two sections assessed per foot. Scale bars, 200
μm. Yellow arrows, moderate to severe synovitis; white arrows, absent or mild synovitis *P < 0.05,
****P < 0.0001 (Kruskal-Wallis with Dunn’s post hoc analysis).
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Figure 3.6 Flow cytometry analysis of infiltrating leukocytes in the feet of mice on day 7 after infection
with CHIKV
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. Mice received at day 3 a single
intraperitoneal injection of 600 μg of isotype control antibody, 300 μg of CTLA4-Ig, 300 μg of anti-CHIKV
mAb, or 300 μg of CTLA4-Ig and 300 μg of anti-CHIKV mAb. (A) Gating strategy showing subpopulations
of live CD45+ cells, including the percentages of CD11b+Ly6C+ inflammatory monocytes, followed by
CD3 and CD4 expression (lower panel) in the remaining Ly6C-negative cells (red arrow) isolated from the
feet of mice from each treatment group. (B to G) Total number of isolated CD45+, CD4+, CD8+,
Ly6C+CD11b+, NK1.1+, and Ly6G+ cells from the feet of CHIKV-infected mice in each treatment group.
Results are pooled from two independent experiments with 4 to 5 mice per group in each experiment. Data
represent the means ± SEM. **P < 0.005, ***P < 0.0005, ****P < 0.0001 (Kruskal-Wallis with Dunn’s
post hoc analysis).
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Figure 3.7 Clinical assessment of the response to CTLA4-Ig treatment in CHIKV-infected WT and
TCRβδ−/− mice
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. (A and B) Foot swelling in WT
(A) and TCRβδ−/− (B) mice from day 1 through 7 in mice receiving at day 3 a single IP injection of 300 μg
of isotype control antibody or 300 μg of CTLA4-Ig. (C) Increase in foot swelling (area in square millimeter)
on day 7 after infection in control- and CTLA4-Ig–treated WT and TCRβδ−/− mice. ns, not significant.
Measurements were conducted in a blinded fashion. Results are pooled from two or three independent
experiments with total n = 16 to 18 per group for WT animals and n = 12 to 13 per group
for TCRβδ−/− animals. Data represent the means ± SEM. **P < 0.005 (two-way ANOVA with multiple
comparisons for swelling curves; Mann-Whitney test for day 7 swelling).
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Figure S3.1 RANKL and OPG expression in CHIKV-infected joints
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. At day 3 after infection, a single
IP injection of 600 μg of isotype control antibody, 300 μg of CTLA4-Ig, 300 μg of anti-CHIKV mAb, or a
combination of 300 μg CTLA4-Ig and 300 μg anti-CHIKV mAb was administered. On day 7 after infection,
RNA was isolated from the left foot. RANKL (A) and OPG (B) expression were measured by qRT-PCR
and normalized to GAPDH. Data were pooled from two independent experiments (n = 10 animals per
group) and analyzed by ANOVA with a multiple comparisons test. P > 0.1 for all groups.
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Figure S3.2 Foot swelling with CTLA4-Ig therapy administered before or during CHIKV infection
Five week-old mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. (A) Foot swelling
(area in mm2) from day 0 through day 7 in mice receiving a single IP injection of 300 μg of isotype control
antibody or 300 μg of CTLA4-Ig at day -1 or day 3. Data are pooled from two independent experiments (n
= 9 or 10 animals per group). Data represent the mean ± SEM. **, P < 0.005; **** P < 0.0001 (2-way
ANOVA with multiple comparisons test).
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Figure S3.3 Flow cytometry analysis of APC activation in the spleen and ankles of mice on day 7 after
infection with CHIKV
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. Mice received at day 3 a single
IP injection of 300 μg of isotype control antibody 300 μg of CTLA4-Ig on either day -1 or day 3 after
infection. (A) Representative contour plots showing the percentages of CD11c+MHCII+ dendritic cells and
CD11bintF4/80+ macrophages in the left foot and spleen of infected animals from each treatment group. (B)
Representative histograms (left panel) and geometric mean fluorescence intensity of CD86 expression on
CD11c+MHCII+ dendritic cells and CD11bintF4/80+ macrophages in the left foot and spleen of infected
animals from each treatment group. Results are pooled from two independent experiments with 3 to 4 mice
per group per experiment. No statistically significant differences were observed in the treatment groups
(Kruskal-Wallis with Dunn’s post-hoc analysis).
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Chapter 4
Summary and Future Directions
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4.1 Summary
CHIKV has rapidly emerged as a global pathogen in little more than a decade, ultimately
infecting millions of people worldwide. Infected individuals experience debilitating myalgia and
polyarthritis that can persist for months to years after infection. An IFN-I response is absolutely
required to control CHIKV and other alphavirus infections. IFN-Is are composed of 14 IFN-α
subtypes and single forms of IFN-β, IFN-ε, IFN-κ, and IFN-ω, and despite their central role in
protection against CHIKV, little is known about the biological roles of individual IFN-I subtypes
during viral infection.
We evaluated the pathogenesis of CHIKV in mice that lack either IFN-α (through IRF7
knockout or IFN-α blocking mAb) or IFN-β (through IFN-β knockout or IFN-β blocking mAb).
We demonstrated that loss of IFN-α greatly impacted CHIKV replication and dissemination. In
contrast, loss of IFN-β exacerbated acute CHIKV disease but without having much impact on viral
loads, suggesting a protective immunomodulatory role. We demonstrated that IFN-β is protective
in CHIKV infection by signaling on nonhematopoietic cells and ultimately limiting neutrophil
recruitment into site of inflammation. Further, the increased clinical disease observed in IFN-β
knockout mice could be rescued with neutrophil depletion. This is distinct from the
immunomodulatory action of IFN-β during LCMV infection, where IFN-β promotes viral
persistence, presumably by increasing infection of CD8α– DCs. Our findings support the growing
evidence of differential functions for IFN-α versus IFN-β and also highlight that distinct
mechanisms can underlie these differences depending on the biological context.
Pathogenesis of CHIKV is still poorly understood but is thought to reflect an interplay
between viral replication and a detrimental immune response. Currently, no approved treatment is
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effective in preventing or controlling CHIKV infection or disease. We examined the efficacy of
several U.S. Food and Drug Administration (FDA)–approved RA therapies in a mouse model of
CHIKV infection. We identified two DMARDs (CTLA4-Ig and tofacitinib) with efficacy during
acute CHIKV arthritis. In particular, CTLA4-Ig, when paired with the neutralizing anti-CHIKV
human mAb 4N12, was highly effective at reducing joint inflammation, periarticular swelling,
migration of inflammatory leukocytes, and infection even when administered several days after
virus inoculation. The concept of combination antiviral and immunomodulatory therapy is a
unique approach for the treatment of infectious diseases. The near-complete effectiveness of
combination therapy in our mouse model of acute CHIKV arthritis has implications for treatment
of other viral infections in which both virus- and immune-mediated pathology result in morbidity
and mortality (for example, influenza and severe acute respiratory syndrome coronavirus). Given
the large number of clinically available biological and small molecular DMARDs, this work may
provide greater impetus for studies that test combination antiviral and immunomodulatory
therapies for the treatment of infectious diseases.
Collectively, these studies highlight that both viral replication and the host immune
responses play important roles in CHIKV pathogenesis. The host immune response has evolved
mechanisms, including IFN-I and likely others, that impede both host- and viral-mediated
pathology. Continued pursuit of delineating host-pathogen interactions will be paramount in
developing effective therapeutic and vaccine strategies to combat emerging tropical diseases,
which remain a global health and economic burden.
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4.2 Future Directions
Our findings demonstrate that IFN-α and IFN-β have distinct protective activities during
acute CHIKV infection. IFN-α appears to be more important for initiating antiviral responses,
whereas IFN-β functions as an immunomodulatory molecule to indirectly limit neutrophilmediated pathology. Additionally, our findings suggest that nonhematopoietic cells are central to
IFN-I mediated control of CHIKV arthritis, consistent with previously published bone marrow
chimera experiments. While these findings have taken important steps to increase our
understanding of IFN-I biology and CHIKV pathogenesis, there are several new questions raised
from these observations. The following sections identify some of these outstanding questions and
discuss future experiments that will aid in further characterizing the actions of IFN-I subtypes
during CHIKV infection.

4.2.1 When and where are IFN-I subtypes induced during CHIKV infection?
Studies of IFN-ε demonstrated that the cell type and context of expression can dramatically
impact the function of an IFN-I subtype. IFN-ε is the only subtype demonstrated to not be regulated
by PRR pathways, but rather, it is constitutively expressed by the epithelium of reproductive
organs and further regulated by sex hormones137. Likely a consequence of its unique regulation,
IFN-ε is the only type I IFN subtype shown to play a protective role against Chlamydia infection,
whereas the other subtypes may worsen disease137,138. There is very little known about differential
expression of IFN-α versus IFN-β in vivo, and their differential properties during LCMV and
CHIKV infection may be due to the timing and location of expression. It may be that loss of IFNα greatly impacts viral replication because the IFN-α’s, but not IFN-β, are primarily expressed
near the cells that are targeted by CHIKV. With the tools currently available, the best way to
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discriminate between the IFN-I subtypes is at the transcript level, through the use of sequence
specific probes. Use of fluorescent in situ hybridization (FISH) for IFN-β, IFN-α4, and at least one
of the IFN-α subtypes induced downstream of IFN-α4/β signaling (e.g. IFN-α2), paired with cell
identifying marker staining would determine the specific cells expressing the various IFN-I
subtypes. Using mRNA FISH detection has its caveats, since transcriptional induction is not
equivalent to cytokine activity, but even with these limitations, this type of in vivo analysis has not
been performed before and would still be informative.
Since transcriptional regulation does not perfectly correlate to cytokine activity, tools that
visualize or detect the different IFN-I subtypes at the protein level in vivo are greatly needed. The
advent of CRISPR-Cas9 technology has enabled precise targeted editing or deletion of genes with
rapid results, and Washington University has several core facilities offering these services. Using
this technology we could develop several mice strains that express fluorescently tagged IFN-I
subtypes. IFN-β, IFN-α4, and a non-initiating subtype, like IFN-α2, would be the important
subtypes to initially analyze. Tagging the IFN-I proteins themselves would avoid the caveats of
relying on transcription as a readout of activity or expression, but may alter the activity of the
protein. Most of the available fluorescent labels are much larger than the IFN-I subtypes, so
extensive in vitro characterization would be required to first ensure that the tagged IFN-I is still
functional. Alternatively, we could develop mice that fluorescently report induction of a particular
IFN-I subtype. This scheme would have caveats similar to the FISH transcript detection method,
but would avoid altering the function of the protein and might have better sensitivity compared to
FISH. While there are caveats and limitations for each reporter mouse scheme, both methods
would bypass the brute force screening needed to generate IFN-I subtype specific mAbs.
Altogether, these types of tools will allow spatial and temporal evaluation of IFN-I subtype
96

induction during a viral infection in vivo, and may reveal novel properties that previous expression
readouts from whole tissues might have missed.

4.2.2 How is IFN-α limiting CHIKV replication and dissemination?
The increase in viral replication and spread with the loss of IFN-α could be due to
alterations in tropism, such as spread to immune cells, or be due to increased infection of cells
normally infected by CHIKV (muscle and fibroblasts). This would be determined by
immunohistochemistry (IHC) analysis with CHIKV and CD45 co-staining of the ipsilateral foot
at several time points during acute infection. Given the results with Vav-Cre expressing mice (Fig.
2.4), we expect to see increased CHIKV staining in CD45– cells in IRF7-KO mice and mice treated
with anti-IFN-α mAb compared to WT mice, and we anticipate similar CHIKV staining between
WT and IFN-β-KO mice, given the similarity in viral loads (Fig. 2.3A). These data will allow us
to more conclusively say that nonhematopoietic cells are the key cell types responding to IFN-I
during acute CHIKV infection. An important next question would then be what is the impact of
loss of IFN-I signaling on these specific cell types during CHIKV infection in vivo? To address
this, we would cross the IFNARfl/fl mice to Ckm (muscle creatine kinase) Cre mice, which target
skeletal and cardiac muscle, or Col1a2 (collagen, type 1, alpha 2) Cre mice, which target many
fibroblast cell types205,206. These types of experiments have not been done before and would allow
us to study the impact of IFN-I responses in relevant cell types in vivo.
IFN-I ultimately exert their biological effects through the induction and regulation of ISGs.
There have only been a handful of ISGs described to have anti-CHIKV activity in vitro and in
vivo, including viperin, PKR, GADD34, IFITM3, and tetherin/BST2121,123–127. ISG15 has also been
described to play a protect role during CHIKV infection, but rather than functioning to limit viral
replication, as it does in several other viral systems, the absence of ISG15 during neonatal CHIKV
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infection resulted in increased lethality from a cytokine storm-like phenotype58. There have been
examples of differential ISG induction by IFN-β compared to IFN-α subtypes in vitro. For
example, IFN-β was shown to have more potent osteoclastogenesis activity by its preferential
upregulation of CXCL11 compared to IFN-α2135. Cell type-dependent effects are thought to be the
result of variation in IFNAR surface expression and composition of downstream effector
molecules, such as STATs157. In order to fully understand how IFN-α and IFN-β display distinct
functions in vivo, a more comprehensive evaluation of the ISGs induced downstream of IFN-α
versus IFN-β in the relevant cell types (such as muscle) is warranted. Our lab has established
protocols for culturing primary synovial fibroblasts and myofibers. RNAseq analysis of infected
primary cell cultures in the presence or absence of anti-IFN-α or anti-IFN-β blocking mAb will
allow us to determine if there are IFN-α- or IFN-β-dependent sets of ISGs induced in response to
CHIKV infection. Furthermore, we will be able to evaluate if ISG induction or subtype differences
display cell type specificity (synovial fibroblasts versus myofibers).

4.2.3 What is the role of neutrophils in the pathogenesis of CHIKV-infected
IFN-β-KO mice?
Neutrophils are essential for the increased clinical disease observed in the IFN-β-KO mice
since the phenotype could be rescued with neutrophil depletion. IRF7-KO mice were not originally
included in the analysis of cellular infiltrates and cytokine and chemokine induction because the
drastic difference in viral load between IRF7-KO and WT mice would make it challenging to
interpret the data. Nevertheless, we did run IRF7-KO samples as we were analyzing the WT and
IFN-β-KO samples, and Irf7-/- mice not only recruited more neutrophils but also showed fewer
inflammatory monocytes compared to WT mice (Fig. 4.1A). In contrast with what we observed in
IFN-β-KO mice (Figure 2.6), analysis of cytokine and chemokine induction in the ipsilateral foot
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of IRF7-KO mice revealed elevated CXCL1 and substantially increased G-CSF levels (Fig. 4.1B).
The likely scenario in the IRF7-KO mice is that elevated viral burden is driving increased
inflammation, cell death, and edema, which collectively alter cellular recruitment. Importantly,
despite the increase in neutrophil number, neutrophil depletion had no impact on foot swelling in
IRF7-KO mice (Fig 2.7), which raises the idea that increased neutrophil number alone might not
be responsible for the phenotype in the IFN-β-KO mice. Indeed, we observed elevated IL-9 levels,
and one study demonstrated that synovial fluid from RA patients could increase the activation and
survival of neutrophils ex vivo, but this effect was lost when anti-IL-9 neutralizing antibody was
added161. To determine if the neutrophils themselves are altered in the IFN-β-KO mice, flow
cytometry analysis of neutrophil activation markers and apoptosis, such as iNOS/NOS2
(eBiosciences) or Annexin V staining, would be used.
To understand the molecular mechanism of IFN-β-mediated protection during CHIKV
infection, we need to know how many steps are between IFN-β and altered neutrophil recruitment
and/or function. First, we need to determine if IL-9 is directly involved in the pathogenesis of
CHIKV infection in IFN-β-KO mice, which could be determined by administering a commercially
available anti-IL-9 neutralizing mAb (9C1; Bio X Cell) to IFN-β-KO mice during CHIKV
infection207. If IL-9 is directly involved in the neutrophil phenotype, we should see complete or
partial alleviation of increased foot swelling and neutrophil recruitment in the IFN-β-KO mice. If
this turns out to be the case, the next question would be which cells are making IL-9? To answer
this, we would infect IL-9 fate reporter mice [available at Medical Research Council (MRC), Mill
Hill, UK] with CHIKV in the presence of anti-IFN-β blocking mAb or isotype control antibody.
In a model of lung inflammation, ILC2s were identified as the predominant source of IL-9173, and
this would be consistent with the timing of elevated IL-9 in the IFN-β-KO mice (2 dpi) (Fig. 2.6).
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The potential involvement of ILC2s in the pathogenesis of CHIKV in IFN-β-KO mice
again raises the question of which cell types are responding to IFN-β? Based on the Vav-Cre+
IFNAR1fl/fl mice (Fig. 2.4), we believe that IFN-β is signaling on nonhematopoietic cells. ILC2s
are known to produce IL-9 when stimulated with IL-25, IL-33, and thymic stromal lymphopoietin
(TSLP), which are typically secreted by damaged epithelium barriers174. Synovial fibroblasts
isolated from RA patients have been shown to produce both IL-33 and TSLP175,176. So if we
determine that IL-9 and ILC2s are directly involved in the pathogenesis in the IFN-β-KO mice,
determining the in vivo source of IL-33, IL-25, or TSLP would identify potential cellular targets
of IFN-β. IFN-γ has previously been shown to downregulate IL-33 induction in lung fibroblasts in
a STAT1-dependent manner208, and IFN-I signaling is also able to activate phosphorylated STAT1
homodimers104. These data suggest that IFN-β-mediated regulation of IL-33 is not outside the
realm of possibility. We would use IHC or immunofluorescence co-staining of IL-33 or IL-25 with
cell identifying markers to determine the cells making these cytokines in ipsilateral foot sections
of WT and IFN-β-KO mice.
If flow cytometry does not reveal differences in neutrophil activation and if IL-9
neutralization is protective, we would need to employ RNAseq analysis of isolated neutrophils
(Ly6G+ enrichment, Miltenyi) to understand how neutrophils are contributing to the pathogenesis
in IFN-β-KO mice. Alternatively, if IL-9 blockade has no effect, we would perform RNAseq on
the whole foot tissue to delineate the mechanisms underlying the increased neutrophil recruitment
and/or function in the IFN-β-KO mice compared to WT and IRF7-KO mice. Collectively, these
experiments will yield a more complete picture of how loss of IFN-β activity leads to neutrophilmediated immunopathology during CHIKV infection.
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4.2.4 What roles do IFN-I play during chronic CHIKV disease?
The pathogenesis of chronic CHIKV disease is still poorly understood. CHIKV RNA, but
not infectious virus, persists in the joints and musculoskeletal tissues of patients and animals
infected with various strains of CHIKV52,55,66. This RNA might serve as a PAMP and cause chronic
symptoms by continuously activating the immune system. Consistent with this paradigm,
microarray analysis of the ipsilateral foot of WT mice at 30 days post infection showed not only
elevated expression of IFN-I-related genes, such as IRF7, IFNAR1, and IFN-β, but also
downregulation of known IFN-I negative regulators SOCS1 and TRIM2455. IFN-I can have
detrimental effects during some chronic infections, such as LCMV, by promoting constant
inflammation, but IFN-I are also important for augmenting protective adaptive immune responses,
like the generation of neutralizing antibodies151,152,209. Because Ifnar1-/- mice die so quickly
following CHIKV infection, most studies have focused on understanding the roles of IFN-I during
acute CHIKV pathogenesis and do not examine chronic disease.
To determine the impact of loss of IFN-α or IFN-β on chronic CHIKV disease, we infected
WT, IFN-β-KO, and IRF7-KO mice with 103 pfu CHIKV via a subcutaneous route and then
sacrificed the mice at 28 dpi for persistent CHIKV E1 RNA analysis by qRT-PCR. We found that
IRF7-KO mice had significantly more chronic CHIKV E1 RNA copies present in the ipsilateral
ankle (Fig. 4.2A, left panel, P < 0.01), whereas IFN-β-KO mice displayed no change in chronic
RNA compared to WT mice (Fig. 4.2A, left panel, P > 0.05). Additionally, IRF7-KO mice had
substantially more persistent RNA in the contralateral ankle (Fig. 4.2A, right panel, p < 0.0001),
and in contrast, the IFN-β-KO mice showed only a modest increase in RNA burden compared to
WT mice, which was to a much lesser degree than the increase observed in the IRF7-KO mice
(Fig. 4.2A, right panel, P < 0.01). Importantly, administering anti-IFN-α or anti-IFN-β mAb at 1
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day before infection and again at 1 dpi phenocopied the IRF7-KO and IFN-β-KO mice,
respectively (Fig 4.2B). These data are consistent with what we observed during acute infection,
and the IFN-α’s seem to be more important in limiting persistent CHIKV RNA during chronic
disease compared to IFN-β.
IFN-I are also known to augment antibody production and isotype switching in B cells108.
Neutralizing antibodies are important for clearing infectious virus and limiting persistent CHIKV
RNA, so the elevated CHIKV RNA could either be due to the increased infection of cells early
during infection or be due to a failure to properly control or clear the RNA through adaptive
immune responses210. To assess these possibilities, we infected WT mice with CHIKV and then
administered anti-IFN-α mAb or isotype control antibody at 2 dpi, which is when elevated viral
load is first observed in the IRF7-KO mice but before the generation of adaptive immune responses
(Fig. 2.3A). Blockade of IFN-α at 2 dpi had no impact on foot swelling compared to isotype control
treated mice (Fig. 4.2C), which is in stark contrast to the severe increase in foot swelling seen with
the day -1/+1 blockade regimen (Fig. 2.1B). IFN-α blockade at day 2 also showed no increase in
the viral RNA burden in the ipsilateral ankle (Fig. 4.2D, left panel). Detailed analysis of acute
infectious virus with this blockade regimen still needs to be performed, but these data imply that
IFN-α acts within the first 48 hours to limit clinical foot swelling, presumably through limiting
viral replication at the site of infection. Furthermore, the antiviral activity of IFN-α during the first
48 hours of infection is able limit persistent CHIKV RNA in the ipsilateral ankle at 28 dpi. In
contrast, the contralateral ankle still showed elevated persistent CHIKV RNA with day 2 blockade
of IFN-α (Fig. 4.2D, right panel, P < 0.0001), suggesting that IFN-α activity is needed beyond 2
dpi to limit CHIKV dissemination.
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The increased persistent viral RNA from loss of IFN-α could be due to more cells harboring
CHIKV RNA during chronic time points. Our lab has developed a system to permanently label
cells that survive CHIKV infection using a Cre-expressing CHIKV strain and fluorescent fatereporter mouse. Using this system in conjunction with anti-IFN-α and anti-IFN-β blockade, we
will be able to assess how many and what types of cells are surviving CHIKV infection and how
loss of IFN-α or IFN-β impacts those cells populations. No difference in marked (Cre+) cells could
indicate that IFN-α is impacting the amount of virus produced by an infected cell, rather than
limiting the number of cells infected. Tropism studies during acute infection (discussed in section
4.2.2), would aid in interpreting the results from these chronic experiments. Much more work is
needed to characterize the immune and viral factors contributing to chronic CHIKV disease, and
there are limitations in using mice to study a human virus. However, these studies will still be
beneficial in understanding how IFN-I subtypes function during chronic CHIKV pathogenesis.

4.2.5 Are there dual protective and detrimental roles for IFN-β during
CHIKV infection?
Of all the IFN-I subtypes, IFN-β has the highest known natural affinity for IFNAR, and as
such has been described as the most potent IFN-I subtype for a number of functions, including
anti-proliferative and pro-apoptotic activities. In particular, IFN-β has potent immunomodulatory
activity and is used as a therapeutic agent in multiple sclerosis, providing beneficial
immunomodulatory effects171. In contrast, recent work with LCMV persistent infection
determined that IFN-β was detrimental and promoted viral persistence150. Blockade of IFN-β, but
not IFN-α, improved antiviral T cell responses and lead to clearance of LCMV, recapitulating what
was observed with IFNAR1 blockade150–152. We did not see a significant change in persistent
CHIKV RNA at 28 dpi with the loss of IFN-β (Fig. 4.2A, 4.2B), but given this history of IFN-β in
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mediating chronic inflammation, we expanded our evaluations to ensure we were not missing a
phenotype.
When we performed our chronic CHIKV experiments for WT, IFN-β-KO, and IRF7-KO
mice, we also collected samples for histological analysis. We had a blinded pathologist score the
day 28 H&E slides, and we were surprised to see that 100% of the IFN-β-KO mice received a
score of 0 (no inflammation), whereas the WT and IRF7-KO mice received an average score of
around 1 (mild inflammation) (Fig. 4.3A). This is preliminary data and needs to be repeated to
increase the sample size, but this was a striking observation. For LCMV infection, the clue that
prompted evaluation of a detrimental role for IFN-β during chronic infection came from evaluating
IFN-α versus IFN-β induction. Infection with clone 13 LCMV infection, which yields persistent
infection, revealed a substantial elevation in IFN-β induction compared to the amount that is
induced during infection with the Armstrong strain of LCMV, which yields an acute infection150.
With this in mind, we next evaluated the induction of IFN-β, IFN-α4, and the IFN-α subtypes that
are induced downstream of IFN-α4/β signaling (pan non-IFN-α4) by qRT-PCR at 12 hours post
infection and 28 dpi. Surprisingly, we found that IFN-I induction was much higher at the chronic
time point than at the acute time point, and IFN-β had the highest chronic expression among the
subtypes analyzed (Fig. 4.3B). A hallmark for detrimental IFN-I responses is sustained elevated
expression, and our preliminary data suggest that this might be the case during CHIKV infection.
We know from our acute CHIKV studies, that IFN-β-KO mice have elevated neutrophil
recruitment at 2 dpi. We next asked what would happen if we blocked IFN-β at around the time it
had already performed this beneficial immunomodulatory function. We infected WT mice and
then administered anti-IFN-β mAb at 2 dpi, and we monitored the mice for clinical foot swelling
and then sacrificed them at 28 dpi for persistent RNA analysis. We found that day 2 IFN-β
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blockade promoted quicker resolution of foot swelling compared to isotype control treated mice
(Fig. 4.3C). Persistent RNA analysis at 28 dpi revealed no change in viral RNA burden, indicating
that again, IFN-β seems to be modulating pathology, but not viral load (Fig. 4.3D). It is worth
noting that the protective foot swelling phenotype seen with day 2 IFN-β blockade is modest
compared to other beneficial treatments, such as depleting CD4+ T cells79. However, these
preliminary data suggest that IFN-β may be playing a detrimental role during the resolution of
inflammation. We performed preliminary FACS analysis of immune infiltrates at 7 dpi in control
treated mice or mice that received anti-IFN-β at 2 dpi, and we did not see any drastic changes in
numbers for the expected immune cell populations at this time point, such as CD4+ T cells, CD8+
T cells, NK cells, macrophages, monocytes, or neutrophils (data not shown).
There have been very few studies performed to characterize the resolution phase of clinical
CHIKV disease. At this point, we can only speculate why IFN-β has this paradoxical dual
protective and pathogenic role. It could be that the presence of IFN-β at later time points skews
the activation state of certain cell types that inhibits their ability to promote resolution of
inflammation. Redesigning our flow cytometry panel to allow for more careful evaluation of the
various cell populations that may be involved in resolution inflammation, such as myeloid
suppressor cells or regulatory T cells, will be important in determining how IFN-β is mediating
these detrimental effects. There are so many permeations of myeloid cell phenotypes, that standard
flow cytometry may be insufficient to capture the phenotype. If we are unable to identify altered
cell recruitment or activation by flow cytometry, then we may need to use CYTOF (mass
cytometry) analysis to parse this phenotype.
Collectively, the data from acute CHIKV disease and these preliminary findings with
chronic CHIKV disease suggest that the biological activity of IFN-β is more complicated than
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originally thought. Its protective versus pathogenic functions are likely related to the timing,
concentration, and cellular source of its expression, as well as its unique signaling potential as the
highest affinity IFN-I subtype. IFN-β is administered intramuscularly or subcutaneously as a
treatment for multiple sclerosis, and thus, CHIKV is a relevant model to study the functions of
IFN-β, given the route of infection and tissues and cell types involved in its pathogenesis. Further
delineation of the actions of IFN-β during acute and persistent CHIKV disease will likely yield
important insight into its potential use as a therapeutic agent or target.

4.3 Materials and Methods
Mice
All animal experiments were performed in accordance and with approval of Washington
University Institutional Animal Care and Use Committee guidelines, and all mouse infection
studies were performed in an animal biosafety level 3 laboratory. All experiments were performed
with 4-week-old male mice. C57BL/6J (WT), interferon beta knockout (Ifnb-/-), and IRF7
knockout (Irf7-/-) mice were bred and maintained in our mouse colony before being transferred to
the animal biosafety level 3 laboratory for experiments. Ifnb-/- and Irf7-/- mice bred onto the
C57BL/6J background were generously provided by Michael S. Diamond (Washington University
School of Medicine).
Virus experiments
A recombinant strain of CHIKV (LR2006 OPY1) was generously provided by S. Higgs
(Kansas State University) and generated from in vitro transcribed cDNA, as previously
described177. At 4 weeks of age, mice were inoculated in the left rear footpad with 103 PFU of the
LR2006 OPY1 strain of CHIKV in a volume of 10 μl. Infected mice were monitored daily for foot
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swelling with digital calipers for 28 days. At the termination of experiments mice were sedated
with a ketamine-xylazene cocktail and euthanized, and then perfused via intracardiac injection
with PBS. Tissues (ipsilateral left ankle and contralateral right ankle) were snap frozen in liquid
nitrogen and stored at −80°C until processing for viral RNA burden. “Ankle” refers to distal foot
with the skin and digits removed. Histological analysis and scoring, immune cell infiltrate analysis,
and cytokine and chemokine analysis are detailed in section 2.5.
Real-time qRT-PCR analysis
RNA was extracted from tissue using TRIzol Reagent and an RNeasy Mini Kit (Qiagen).
The TRIzol Reagent manufacturer’s protocol was followed up until removal of the RNAcontaining aqueous phase, to which an equal volume of 100% RNase-free ethanol was added. This
solution was added to the RNeasy column, after which the RNeasy Mini Kit instructions were
followed. The quantity of CHIKV RNA was determined by qRT-PCR using the TaqMan RNAto-CT 1-Step Kit (Applied Biosystems) with an E1-specific primer/probe set203. Absolute copies
of CHIKV E1 was determined by with a copy number standard curve generated from CHIKV
genomic RNA synthesized in vitro. Copy number was calculated using an online program (IDT)
by taking into account the concentration of the RNA (ng/μL), the length of the RNA (11,800 bp
for CHIKV), and nature of the RNA (ssRNA) (http://scienceprimer.com/copy-number-calculatorfor-realtime-pcr).
For IFN-I expression by pRT-PCR, RNA was extracted using a TRIzol and RNeasy Mini
Kit (Qiagen) hybrid protocol outlined above. Two microliters of the extracted RNA from CHIKVinfected or mock-infected mice were analyzed by qRT-PCR. An arbitrary standard curve was
generated for each primer/probe set to generate arbitrary values (SQ) for each gene of interest or
the housekeeping gene, GAPDH (glyceraldehyde-3-phosphate dehydrogenase). Mock and
107

infected SQ values for the gene of interest and GAPDH values were used to calculate ΔΔCt, and
normalized fold change was calculated by 2-ΔΔCt.
IFN-β Fwd: 5’-GGC TTC CAT CAT GAA CAA CAG-3’ Rev: 5’-GTT GAT GGA GAG GGC
TGT G-3’ Probe: 5’-/56FAM/CTG CGT TCC TGC TGT GCT TCT C/36-TAMSp/-3’
IFN-α4 Fwd: 5'-TGT GTG ATG CAG GAA CCT CCT-3' Rev: 5'-GGT ACA CAG TGA TCC
TGT GG-3' Probe: 5'-/56-FAM/AAG ACT CCC TGC TGG CTG TGA GG/36-TAMSp/-3'
Pan non-IFNα4 Fwd: 5'-ARS YTG TST GAT GCA RCA GGT-3' Rev: 5'-GGW ACA CAG
TGA TCC TGT GG-3' Probe: 5'-/56-FAM/CAG GAA CCT CCT CTG ACC CAG GA/36TAMSp/-3'
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4.4 Figures

Figure 4.1 IRF7-KO mice have increased neutrophil recruitment with elevated CXCL1 and G-CSF
WT and IRF7-KO mice were infected with 103 pfu CHIKV. (A) Flow cytometry analysis of immune
infiltrates from digested ipsilateral foot tissue at 2 and 3 dpi. (B) Cytokine and chemokine levels in the
ipsilateral foot were determined using Luminex technology (Millipore). Results are pooled from two
independent experiments with n = 6-7 mice per group. Data represent the mean ± SEM. *, p<0.05; **,
p<0.01; ***, p<0.001; ****, p<0.0001 (1-way ANOVA with Tukey’s post-hoc multiple comparisons test).
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Figure 4.2 IFN-α limits persistent CHIKV RNA in the ipsilateral ankle within the first 48 hours
following CHIKV infection
(A) WT, IFN-β-KO, or IRF7-KO mice were infected with 103 CHIKV and sacrificed at 28 dpi for CHIKV
RNA analysis. (B) WT mice were treated with 1 mg of anti-mouse IFN-α (TIF-3C5), 1 mg anti-mouse IFNβ (HDβ-4A7), or 1 mg isotype control antibody at 24h prior to and again 24h post infection by IP route and
then sacrificed at 28 dpi for CHIKV RNA analysis. (C) WT mice were treated with 1 mg of anti-mouse
IFN-α (TIF-3C5) or 1 mg isotype control antibody at 2 dpi and measured daily for foot swelling and then
(D) sacrificed at 28 dpi for CHIKV RNA analysis. (A,B, D) Absolute copies of CHIKV E1 was determined
by qRT-PCR and a standard curve generated from CHIKV genomic RNA synthesized in vitro. Dashed line
represents the limit of detection. Ips, ipsilateral; contr, contralateral. *, p<0.05; **, p<0.01; ***, p<0.001;
****, p<0.0001 (1-way ANOVA with Tukey’s post-hoc multiple comparisons analysis for RNA analysis;
2-way ANOVA with Dunnett’s multiple comparisons for foot swelling).
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Figure 4.3 IFN-β may have detrimental effects during chronic CHIKV pathogenesis
(A) WT, IFN-β-KO, or IRF7-KO mice were infected with 103 pfu of CHIKV subcutaneously in the left
rear foot, and the infected foot was harvested at 28 dpi for histological analysis. H&E slides from d28 were
scored on a scale of 0 to 3 by a blinded pathologist for overall inflammation, taking into consideration joint
space inflammation, myositis, and synovitis for scoring. Criteria were: 0, no inflammation; 1, mild
inflammation; 2, moderate inflammation; 3, severe inflammation. Data are pooled from 2 independent
experiments with n = 4-5 per group. (B) WT mice were infected with CHIKV and the infected ankle was
harvested at 12 hours or 28 days post infection for RNA extraction. RT-PCR was used to determine the
expression of IFN-β, IFN-α, or pan non-IFN-α4 subtypes. n = 4 per group. (C) WT mice were treated with
1 mg of anti-mouse IFN-β (HDb-4A7) or 1 mg isotype control antibody at 48 hours post infection, and the
infected foot was measured daily with digital calipers and then (D) sacrificed for CHIKV E1 RNA at 28
dpi. All data are represented as mean ± SEM, and if no error bar is present that indicates the error is smaller
than the height of the symbol. The data are pooled from 2 independent experiments with n = 6-7 mice per
group. *, p<0.05; **, p<0.01; ****, p<0.0001 (2-way repeated measure ANOVA with Dunnett’s post-hoc
multiple comparisons analysis for foot swelling; 1-way ANOVA with Tukey’s multiple comparisons for
inflammation score; Mann-Whitney test for CHIKV E1 RNA burden).
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